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 This thesis is comprised of a scoping literature review, a research paper and critical 
appraisal which focus on psychological distress and psychological therapy in the context of 
Huntington’s disease (HD).  The literature review is a scoping review of 29 papers looking at 
different aspects of irritability in the context of HD.  The review examines the validity of 
irritability as a meaningful construct in HD.  Clinical and theoretical implications as well as 
suggestions for further research are also discussed.   
 The research paper investigates understandings of psychological distress in HD from 
the perspective of people with HD as well as seeking to understand people’s perspectives of 
psychological therapy.  Semi-structured interviews were conducted with nine participants, 
prior to commencing a trial of mindfulness-based cognitive therapy (MBCT) and the data 
subsequently analysed using interpretative phenomenological analysis (IPA).  Three themes 
emerged from the data: (1) Attributing psychological distress to HD: “you’re blaming 
everything on that now”; (2) Attribution across time: “in the past you’d just get on with it”; 
(3) Therapy instils hope and fight: “a light at the end of the tunnel”.  The results are then 
discussed in terms of implications for the potential for psychological services to be available 
to people with HD alongside the need for further research into the acceptability of 
psychological approaches in the context of HD.  The research paper highlights a predominant 
biological understanding of psychological distress with a more implicit psychological 
understanding presented, and a hope for psychological therapy to enable people to regain 
control over their experience.   
 Finally, the critical appraisal reflects on some of the process issues encountered 
during the research including the impact of attending the MBCT group on the data analysis 
and barriers to recruitment.   
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IRRITABILITY IN HUNTINGTON’S DISEASE  
 
Abstract 
Purpose: To scope the literature concerning irritability in Huntington’s disease to determine 
whether or not irritability is a valid and meaningful construct within this population. 
Method: Scoping literature review. 
Results: The review highlighted several aspects of irritability in HD which influence the 
validity of irritability as an independent construct within HD.  Various measures are used to 
assess irritability yet there remains no gold standard and consequently irritability is assessed 
inconsistently.  Irritability does not seem to reflect the HD disease process and appears to be 
strongly associated with other psychological constructs including depression, anxiety and 
apathy.      
Conclusions: Irritability as a construct continues to lack clarity and is used and measured 
inconsistently.  Consequently, further research is required in order to determine the extent to 
which irritability is a valid construct within the context of HD.     
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Validity of irritability in Huntington’s disease: A scoping review 
It has been suggested that irritability is commonly experienced by people with 
neurological conditions such as Parkinson’s disease (PD; Aarsland et al., 1999), dementia 
(Burns, Folstein, Brandt & Folstein, 1990) and progressive supranuclear palsy (PSP; 
Gerstenecker, Duff, Mast, Litvan & ENGENE-PSP Study Group, 2013).  However, it is 
perhaps most notably discussed in people with Huntington’s disease (HD; Wagle, Wagle, 
Markova & Berrios, 2000) where it is often reported as a ‘neuropsychiatric’ symptom of the 
HD process.  Moreover, many studies have reported high rates of irritability in HD (Craufurd, 
Thompson & Snowden, 2001; van Duijn, Kingma & van der Mast, 2007).  However, it has 
been argued the concept as it is currently lacks psychological rigour and, as such, research 
and measures could be potentially measuring different concepts, for example anger and 
aggression (Craig, Heitanen, Markova & Berrios, 2008).   
Introduction to Huntington’s disease 
HD is an inherited neurodegenerative disease, characterised by a triad of progressive 
difficulties in motor, cognitive and behavioural domains (Craufurd et al., 2001).  A formal 
diagnosis of HD is made when motor symptoms become apparent (Tabrizi et al., 2009).  Age 
of onset (when motor symptoms start to develop) usually occurs around the age of 40 with 
the disease subsequently progressing over 15-20 years (Novak & Tabrizi, 2010).  However, 
psychological difficulties are frequently experienced by people with HD prior to this onset of 
motor symptoms (Duff et al., 2007; Roos, 2014).  Difficulties associated with HD vary across 
disease stages, with psychological difficulties such as irritability, depression and anxiety 
argued to form the three core difficulties experienced by people with HD (Kloppel et al., 
2010).   
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Conceptualising Irritability 
Irritability, in general, has been characterised as a readiness to react excessively to 
negative stimuli often having both an affective component, anger and behavioural 
component, aggression (Buss & Durkee, 1957; Caprara et al., 1985), however it is poorly 
defined.  Snaith, Constantopoulos, Jardine and McGuffin (1978) defined irritability, in 
general, as a psychological state characterised by poorly controlled anger resulting in 
aggression, impatience and intolerance.  However, in an attempt to provide a formal 
definition, Snaith and Taylor (1985) later proposed a definition of irritability as a “feeling 
state characterised by reduced control over temper which usually results in irascible verbal or 
behavioural outbursts, although the mood may be present without observed manifestation” 
(p.128).  This seems to be inconsistent with psychological theory which differentiates 
between an emotion and a mood, seeing them as closely related yet distinct phenomena 
(Beedie, Terry & Lane, 2005).  They further noted “it may be experienced as brief 
episodes…or it may be prolonged and generalised…irritability is always unpleasant for the 
individual and overt manifestation lacks the cathartic effect of justified outbursts of anger” 
(Beedie et al., 2005, p.128).     
More recently, Craig et al. (2008) conceptualised irritability as a mood state, 
differentiating this from emotions such as anger which tend to be more reactive compared 
with a mood which they understood to be more prolonged.  Conversely, irritability has also 
been conceptualised as a stable personality trait (Buss & Durkee, 1957).  For example, early 
German psychopathologists referred to changes in behaviour, such as irritability, as part of 
personality change (Craufurd & Snowden, 2014).  Indeed, it is evident that there are opposing 
views as to whether irritability should be conceptualised as a state or trait (Burns et al., 1990), 
or if it has elements of both.   
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Indeed, the debate remains regarding whether irritability should be understood as a 
mood disorder independent of others such as anxiety and depression (Mangelli et al., 2006).  
In a study investigating irritability in physical illness including cardiovascular, cancer and 
endocrine illnesses, Mangelli et al. (2006) found irritability and depression to be two distinct 
phenomena despite some overlap.  They argued this provided support for the earlier findings 
of Snaith and Taylor (1985) that irritability was an independent mood as opposed to one 
representative of anxiety or depression.  
Irritability in HD, specifically, has been conceptualised using the definitions applied 
to the general population.  However, the occurrence of irritability in HD can be more difficult 
to determine due to the brain changes associated with HD, potential differences in 
understandings of irritability and the lack of reliable methods of assessment (Craufurd & 
Snowden, 2014).   
Causes of Irritability in HD  
 In addition to the variety of definitions of irritability and measures used to assess it, 
various explanations have been put forward regarding the cause of irritability in HD 
(Craufurd & Snowden, 2014).  It is commonly understood that irritability is the result of the 
biological progressive neurodegenerative nature of HD.  Indeed it has been suggested that 
higher levels of irritability in people with HD, compared with spouse controls in the same 
environment, “implicates a neurobiological, rather than psychological or reactive, basis for 
these behavioural signs” (Tabrizi et al., 2009, p.799).  For example, it has been suggested that 
the degeneration in areas of the brain that control socially appropriate behaviour may result in 
irritability in the earlier stages of HD (Mega & Cummings, 1994).  Moreover, this is 
consistent with wider understandings that neurodegenerative changes resulting from HD are 
important in the development of psychological difficulties experienced by people with HD.   
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While irritability is frequently identified as a separate difficulty experienced in HD, 
there has also been debate that it may be secondary to other psychological difficulties such as 
depression (Craufurd & Snowden, 2014; van Duijn., 2010).  Furthermore, some people with 
HD often report periods of suicidal ideation after episodes of heightened irritability (Craufurd 
& Snowden, 2002), indicating a potential association between irritability and suicidality.  On 
the other hand, it has been suggested that irritability may, at least in part, be a psychological 
consequence of difficulties with communication and cognition (Craufurd & Snowden, 2014).  
Difficulty communicating would understandably lead to frustration, over time resulting in an 
increased level of irritability.  
Although the dominant perspective is that of a biological understanding, behaviour in 
HD is also likely to reflect both intrinsic and reactive changes (Craufurd & Snowden, 2014).  
Consequently, further investigation is required of the concept of irritability in HD to 
understand whether the occurrence of irritability is a result of alterations in the brain, in 
response to living with a distressing disease or a combination of the two.  Indeed, irritability 
is noted to be a key determinant in people with HD moving to residential care (Craig et al., 
2008) and as such it seems important to understand the concept to reduce the impact it has on 
people with HD.  Furthermore, the influence different measures have on reports of irritability 
should also be considered. 
Validity of irritability  
  There are several types of validity important in terms of establishing whether a 
construct is valid, for example construct validity, predictive validity, convergent validity and 
discriminant validity (Kendell, 1975).  Construct validity refers to how much the concept of 
irritability as a symptom in HD is reflective of a true difficulty that people with HD 
experience (Kendell, 1975).  
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As part of assessing construct validity, which could be seen as a superordinate value, 
a number of other types of validity can also be assessed.  For example, convergent validity 
refers to the degree to which a construct is similar to another construct that it should be 
similar to.  In the case of the current review, this relates to whether irritability is similar to 
constructs such as anger and hostility.  Additionally, in terms of the measures used to assess 
irritability, it is important to consider whether they measure irritability in a similar way or 
whether they distinguish between different constructs.  Conversely, if it were apparent that 
irritability was to diverge in meaningful ways from other constructs then it could be 
suggested that irritability has discriminant validity.  Discriminant validity refers to whether or 
not a diagnosis or measure can distinguish between the construct we are interested in and 
other constructs (Kendell, 1975).  Finally, predictive validity is the extent to which a 
diagnosis provides useful information regarding an individual’s future (Kendell, 1975).  For 
example, reviewing the literature and considering whether or not irritability is able to predict 
important aspects of HD such as quality of life and disease progression.   
In order to examine the concept of irritability the current review adopts a scoping 
review method.  A scoping review aims to provide an overview of background information 
pertaining to an area of inquiry which can later inform a more specifically focussed 
systematic review (Armstrong, Hall, Doyle & Waters, 2011).  Scoping reviews are 
particularly useful for areas which are complex and have not been extensively reviewed 
(Mays, Roberts & Popay, 2001).  Indeed, irritability in HD has received little attention and is 
yet to be fully understood.  As such, this scoping review aims to provide a broad overview of 
the existing literature on irritability in HD to investigate whether irritability could be argued 
to be a valid construct within this population.  Consequently, this paper will review the key 
findings from the research, how irritability is associated with other psychological difficulties, 
potential treatment options for people with HD and the potential aetiology of HD.  Finally, it 
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will conclude whether or not irritability is a valid construct and clinically meaningful for 
people with HD.   
Method 
 This scoping review followed the stages outlined by Arksey and O’Malley (2005).  A 
research question was developed and relevant studies identified.  Studies appropriate for 
inclusion were selected and the relevant data charted in order to collate the necessary data.  
The results were then summarised and reported.   
Searching for studies 
The papers selected for inclusion in this scoping review met the following inclusion 
criteria: (i) the paper was published in English language; (ii) published in a peer reviewed 
journal; (iii) the paper involved the investigation of irritability in HD including prevalence, 
associations with other variables, across disease stage, treatment options and aetiology.  
Additionally, papers investigating irritability in HD and other neurological conditions were 
excluded if they did not report findings for each separate neurological condition.   
Relevant papers were identified by conducting a search in the databases Academic 
Search Complete (searchable years 2002-2014, ‘peer reviewed’ and ‘English’ selected), 
PsycINFO (searchable years 1940-2015, ‘peer reviewed’ and ‘English’ selected), CINAHL 
(searchable years 1999-2009, ‘peer reviewed’ selected), Scopus (searchable years 2006-2015, 
‘English’ and ‘Journals’ selected), and Web of Science (searchable years 1990-2015).  The 
search was conducted in November 2015 and the full-text search terms used to identify 
potential papers were “irritability” and “Huntington*”.  This database search returned 334 
papers (Academic Search Complete = 29, PsycINFO = 60, CINAHL = 3, Scopus = 179 and 
Web of Science = 63).  Duplicates were removed, leaving 217 papers.  Remaining papers 
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were then reviewed for their suitability by reading the titles and abstracts.  However, for 
those papers where suitability was unclear, the full text was read and subsequently the 
inclusion and exclusion criteria applied.  This process revealed 29 papers suitable for 
inclusion in the current review.  Table 1 provides a summary of these papers.  Quality 
appraisal is not required within the process of a scoping review therefore was not conducted 
(Arksey & O’Malley, 2005).      
(<Insert Table 1 here>) 
Results 
 Twenty-nine papers were included in the current review with a summary of the results 
presented in Table 2.  Of the 29 papers, 10 compare irritability in people with HD to healthy 
controls, nine examine changes in irritability across disease stage, two compare irritability in 
individuals with HD with those with other neurological conditions, 12 report associations 
with other psychological difficulties in HD, three describe interventions and three report 
potential neurological pathways for irritability in HD.  Some of these papers investigate more 
than one area pertaining to irritability in HD.  In addition, the measures used to assess 
irritability are also discussed below.  
(<Insert Table 2 here>) 
 Measures of Irritability 
Various measures have been developed to assess irritability both in non-HD and HD 
populations, for example, the Buss-Durkee Hostility Inventory (BDHI) and the Problem 
Behaviours Assessment for HD (PBA-HD).  However, it remains that there is no gold 
standard for assessing irritability (Bouwens, van Duijn, van der Mast, Roos & Guiltay, 2015).  
Furthermore, the lack of a core and widely understood construct means that different 
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measures potentially measure different constructs.  This can result in inconsistencies in 
research findings based on the choice of measures as opposed to true differences based on 
issues unrelated to sampling error.  Furthermore, irritability measures can rely on either self-
report, caregiver-report, clinician-based assessment and in some cases a combination of the 
three.   
A number of measures are used to assess irritability in HD (see Table 3).  The 
Irritability, Depression, Anxiety Scale (IDA; Snaith et al., 1978) was initially developed to 
address the need for scales to assess irritability in clinical populations and has been used in 
studies assessing irritability in HD (Berrios et al., 2001; Berrios et al., 2002; Nimmagadda, 
Agrawal, Worrall-Davies, Markova & Rickards, 2011).  Snaith et al. (1978) described 
irritability as a two-dimensional construct, which led to the formation of two subscales in the 
IDA: outwardly expressed irritability and inwardly expressed irritability (Snaith & Taylor, 
1985).  Additionally, this scale is reliant on self-report, thus assessing subjective irritability.  
Snaith and Taylor (1985) examined irritability in clinical populations, across four studies 
including people experiencing depression, anxiety, mood disorder and obsessional neurosis, 
which subsequently indicated that irritability should be understood as a mood state rather 
than a personality trait.   
(<Insert Table 3 here>) 
 Further measures that have been used to assess irritability in HD include self-report 
measures such as the PBA-HD (Craufurd et al., 2001) and the behavioural section of the 
Unified Huntington’s Disease Rating Scale (UHDRS-b) and informant report measures such 
as the John Hopkins Irritability Scale and the Burns Irritability Scale (BIS; Burns et al., 
1990).  Burns et al. (1990) argue that self-report measures are not suitable for people who go 
on to develop cognitive impairment, potentially suggesting that people lack insight into their 
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own problems and thus require more objective measures.  As such, informant report measures 
can be used alongside self-report measures to provide a more accurate account of a person’s 
experience of irritability.  The BIS (Burns et al., 1990) purports to allow for an objective 
measure of irritability to be obtained from a carer or family member, aiming to measure a 
change in behaviour in the context of illness.  Therefore, someone who has always been 
irritable would be unlikely to score highly for irritability using this scale (Burns et al., 1990) 
due to the focus on change in irritability as opposed solely to the current level.   
One of the most commonly used measures is The Unified Huntington’s Disease 
Rating Scale (UHDRS; Huntington Study Group, 1996) which measures motor, cognitive and 
behavioural aspects of HD as well as functional capacity.  Indeed, this scale was used in a 
number of studies included in the current review (Banaszkiewicz et al., 2012; Hubers et al., 
2013; Reedeker et al., 2012; Rickards et al., 2011; Thompson, Snowden, Craufurd & Neary, 
2002; Van Duijn et al., 2014).  
Another measure frequently used to measure irritability in HD is the PBA-HD 
(Craufurd et al., 2001).  This is a semi-structured interview used with both people with HD 
and close others such as family members.  The scale comprises of three factors: apathy, 
irritability and depression, all with individual sub-scale items.  Irritability items include 
inflexibility, preoccupations, irritability and verbal and physical aggression (Craufurd et al., 
2001).  Items are measured on a five-point scale to assess both the frequency and severity of 
behavioural difficulties in HD and multiplied to obtain an overall score (Gregory et al., 
2015).    
Indeed, it is evident that the way in which different measures conceptualise, and 
subsequently measure, irritability has differed.  Although multi-item irritability measures 
such as the IRQ have been shown to have good reliability and assess a variation of thoughts, 
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feelings and behaviours related to irritability (Holtzman, O’Connor, Barata & Stewart, 2015), 
shortcomings have been highlighted.  Holtzman et al. (2015) note how scales attempting to 
measure irritability also tap into constructs such as anger and hostility.  This is problematic in 
the assessment of irritability since irritability, unlike anger, often occurs in the absence of a 
direct cause and is longer in duration (Beedie et al., 2005), therefore implying a different 
construct.  If irritability is to be understood as a mood state then it should be distinguished 
from anger which often has a clear antecedent (Craig et al., 2008).  Although it is generally 
acknowledged that irritability is a construct distinct from anger and aggression, this is not 
currently reflected in the measures used to assess it (Holtzman et al., 2015).   
In addition, if irritability is conceptualised as a “temporary psychological state” 
(Snaith et al., 1978, p.164) then it seems necessary that the individual is central in the rating 
process (Holtzman et al., 2015).  Self-report measures, where possible, are one of the key 
methods of measuring irritability in HD.  They are important in order to understand and 
measure the personal experience of the individual which is not always observable by family 
members or clinicians, since their ratings are based on observable behaviour (Bogart, 2011).  
However, in contrast to this, consideration should be given to the fact that with conditions 
such as HD which affect the brain, there is a potential for self-awareness to become reduced 
further along in the disease process (Kirkwood et al., 2002b).  As such, there may be a limit 
to the validity of self-report measures.      
Indeed, it may be difficult to measure irritability in HD accurately, particularly during 
more advanced stages whereby an individual may not be able to provide a self-report measure 
due to other difficulties that occur with the progression of HD such as cognitive impairment 
(Fisher, Sewell, Brown & Churchyard, 2014).  As such, it may be at this point that family 
member and clinician-based measures are more appropriate, either as a stand-alone measure 
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or in addition to self-report measures.  However, if the notion of inward irritability, that 
which cannot be observed, is to be considered then this is likely to go un-measured due to the 
reliance on self-report measures (Snaith et al., 1978).  Consequently, reported rates of 
irritability in HD may depend on the measures used, how irritability is defined and the stage 
of disease (van Duijn et al., 2013).  Measures such as the PBA-HD which are conducted with 
the person with HD, a spouse or carer and acknowledge observations made by the interviewer 
(Callaghan et al., 2015), may be most appropriate.  Furthermore, it may also be important to 
consider whether a single measure of irritability is able to provide an accurate depiction of 
irritability (Kloppel et al., 2010).    
Irritability in people with HD compared with healthy controls 
A range of studies have compared irritability in people with HD with healthy controls 
(Berrios et al., 2001; Berrios et al., 2002; Julien et al., 2007; Kirkwood et al., 2002a; 
Kirkwood et al., 2002b; Kingma, van Duijn, Tinman, van der Mast & Roos, 2008; Kloppel et 
al., 2010; Reedeker et al., 2012; van den Stock et al., 2015; Vassos, Panas, Kladi & 
Vassilopoulos, 2007).  Seven of the 10 studies found that irritability is significantly higher in 
people with HD compared with healthy controls (Berrios et al., 2001; Berrios et al., 2002; 
Julien et al., 2007; Kingma et al., 2008; Kirkwood et al., 2002a; Reedeker et al., 2012; Van 
den Stock et al., 2015).  In a review of the prevalence of psychological difficulties in HD, van 
Duijn et al. (2007) found reported rates of irritability in people with HD to range from 38% to 
73% as measured by the PBA-HD and NPI.  As cut off scores are used to determine whether 
irritability is present, and to what extent, it is apparent there is an assumption that irritability 
is a symptom of HD which can be diagnosed.  However, due to no standardised cut off score 
existing for measuring irritability, across different measures, those selected are at the 
discretion of the researcher.    
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Additionally, irritability levels have been found to vary in accordance with report 
type.  There was agreement between both self-report and informant-report that 28% of those 
with the expanded gene were considered irritable and 50% were not irritable.  With regards to 
the remaining participants, there was disagreement between people with HD and their 
informants with informants reporting more irritability in people with HD compared with the 
individuals themselves (Reedeker et al., 2012).  This could potentially be a result of people 
with HD having reduced insight into their experience and presentation.     
In addition, Kirkwood et al. (2002a) observed an increase in irritability and clinical 
hostility over an average of a 3.7-year period in pre-symptomatic gene carriers compared 
with non-gene carriers.  This demonstrated that irritability may occur prior to the occurrence 
of physical clinical symptoms.  Similarly, Berrios et al. (2002) found that gene carriers had a 
significantly higher level of both inward and outward irritability than non-gene carriers 
measured by the SIS, which loaded onto the ‘personality’ factor suggesting irritability may be 
part of a personality change occurring in HD.   
   However, three out of the ten studies which compared people with HD to healthy 
controls failed to find a significant difference in irritability (Kirkwood et al., 2002b; Kloppel 
et al., 2010; Vassos et al., 2007).  Kloppel et al. (2010) did not find a significant difference in 
irritability between pre-symptomatic gene carriers and non-gene carriers.  Additionally, there 
was agreement between the pre-symptomatic gene carriers group and their close companions 
regarding their level of irritability.  Due to the inclusion of informant-report in addition to 
self-report, it may be suggested that the potential for under-reporting and limited insight is 
reduced, thus reflecting a more accurate depiction of their irritability.   
Similarly to Kloppel et al. (2010), Kirkwood et al. (2002b) did not find a difference in 
irritability between those with manifest HD, pre-symptomatic gene carriers and non-gene 
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carriers as measured by the MMPI.   It is noted that the MMPI may not be sensitive to 
changes observed in HD (Kirkwood et al., 2002b) due to it being a measure of personality 
traits and psychopathology used within non-HD populations.  However, the use of the SIS 
constructed for use with clinical populations, in the study by Kloppel et al. (2010), was not 
able to detect differences in irritability between pre-symptomatic gene carriers and non-gene 
carriers.  It may therefore be argued that the selected measure was not the only reason for 
lack of significant results.  Additionally, the control group in this study were companions of 
those with HD and thus indirectly affected by HD.  Therefore, their experience of irritability 
may differ to healthy controls who are not affected by HD.                
Finally, Vassos et al. (2007) investigated the psychological and behavioural features 
which differentiate people with HD from those without HD.  Within this study they did not 
find a significant difference in either inward or outward irritability as measured by the SIS.  
This is in contrast to the findings of Berrios et al. (2002) who also used the SIS as a measure 
of irritability.  On examining the effect size for the study by Vassos et al. (2007), a small 
effect size of d = 0.20 for inward irritability suggests an effect is potentially detectable, 
however an effect size of d = 0.06 for outward irritability suggests there is no difference to 
find.  Indeed, the sample included by Vassos et al. (2007) was n = 64 while Berrios et al. 
(2002) had a sample size of n = 98.  However, Vassos et al. (2007) did find that people with 
HD showed a significantly higher level of extroverted hostility compared with healthy 
controls, describing hostility as a personality dimension rather than a behavioural aspect.  
Similarly, Berrios et al. (2002) found that both inward and outward irritability loaded onto a 
personality factor for people with HD within their factor structure suggesting irritability may 
be part of a person’s personality.   
Irritability across disease stage 
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While gene carriers have been compared with healthy controls, it has been suggested 
that irritability varies across stage of disease, potentially with those closer to the onset of 
clinical symptoms becoming increasingly more irritable.  In addition, irritability may reflect a 
change in people with HD for a substantial period prior to the onset of motor symptoms 
(Julien et al., 2007). As such, a comparison of people with HD across disease stage seems 
appropriate in order to understand the trajectory of irritability in HD.   
Of the ten papers included in this review comparing irritability across disease stage, 
seven did not find a significant difference in irritability across disease stage (Bouwens et al., 
2015; Craufurd et al., 2001; Julien et al., 2006; Kingma et al., 2008; Kirkwood et al., 2002b; 
Pflanz, Besson, Ebmeier & Simpson, 1991; van Duijn et al., 2013).  Included among the 
more cross sectional studies were two longitudinal studies which also found no significant 
increase in irritability between baseline (two years after entering the study) and two-year 
follow-up (Bouwens et al., 2015; van Duijn et al., 2013).  Bouwens et al. (2015) took 
measurements of irritability at two time points using the Irritability Scale (Chatterjee, 
Anderson, Moskoqitz, Hauser & Marder, 2005) and found of those who were irritable at 
baseline, i.e. two years after entering the study (33%), 70% remained irritable at follow-up 
two years later.  Furthermore, of those who were not irritable at baseline, only 23% went on 
to report irritability at follow-up.    
Similarly, in a study by Craufurd et al. (2001), no linear relationship emerged between 
irritability and disease duration.  However, across a disease duration span of 1-23 years, they 
found that difficulties defined under the factor ‘irritability’, including irritability, verbal 
aggression, physical aggression, inflexibility and pathologic preoccupation, occurred more 
frequently in people with a disease duration of 6-11 years.  Interestingly, they found a linear 
relationship between apathy and disease duration which they argued might suggest apathy 
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reflects a disease process whereas irritability may not.  Consistent with the finding that 
apathy increases with disease progression, Kingma et al. (2008) found that both early 
symptomatic and advanced symptomatic gene carriers did not reveal more irritability than 
pre-symptomatic gene carriers, however did show more apathy the further advanced in 
disease they were.  Again, this suggests that irritability may not be an underlying process 
associated with the disease process of HD, rather it is in response to living with HD.        
However, three papers did find a difference in irritability across disease stage 
(Gregory et al., 2015; Thompson et al., 2012; van Duijn et al., 2014), although their findings 
were not consistent.  Irritability was found to be significantly higher in those with clinically 
diagnosed early HD when compared with people with pre-manifest HD.  However, this 
research was not extended to those with more advanced HD (Gregory et al., 2015).  Van 
Duijn et al. (2014) found that in people with HD who experienced moderate to severe 
irritability, this increased by stage of disease from 10.4% at stage 1 to 19.6% at stages 4-5.  
However, this increase at such an advanced stage could potentially be seen as general distress 
due to the impact of HD at this stage.  Similarly, a longitudinal study by Thompson et al. 
(2012) showed an increase in irritability over time as measured by the PBA-HD.  Irritability 
was marked as being present if participants scored a severity score of greater than or equal to 
2.  However, this was limited to a significant linear effect in those who entered the study at 
stage 1 and 2 but not in those who entered at stage 3 of HD.  The progression of irritability 
was therefore only evident in early stage HD.  On discussing these findings, Thompson et al. 
(2012) note that irritability was common among their sample, further describing poor temper 
control in 80% of participants and physical aggression in 50%.  Indeed, it appears that temper 
and aggression, frequently measured independently of irritability are assumed, in this study, 
to be aspects of irritability as opposed to separate constructs.   
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However, when interpreting the findings, consideration should be given to studies in 
which participants were taking medication to manage their irritability and the impact this may 
have had on reports of irritability.  Participants in the study by Thompson et al. (2012) had 
access to psychiatric input and therefore may have been taking medication to manage their 
irritability.  As irritability only increased during the early stages of HD, it is possible that 
people were prescribed medication when it started to impact on their quality of life.  
Consequently, if irritability is managed in the later stages then it is possible that the level of 
irritability may not continue to progress due to medication being accessed.  Similarly, 
Craufurd et al. (2001) reported 35% of participants to be taking medication to manage 
irritability.  Consequently, differences in findings across studies may be influenced by the 
current treatment options being accessed by people with HD included in the studies.   
Comparing HD with other neurodegenerative conditions 
Since irritability has been reported to occur in neurological conditions other than HD, 
it seems appropriate to compare irritability in people with HD with people with other 
neurodegenerative conditions.  Burns et al. (1990) compared people with HD with people 
with Alzheimer’s Disease (AD) on irritability and apathy using an irritability/apathy scale 
developed for their research.  They found no significant difference in irritability (58%) or 
apathy (48%) between the HD and AD groups.  The HD group were significantly more 
aggressive than the AD group with their aggressive outbursts lasting longer.  Additionally, in 
both groups, irritability, apathy and aggression appeared to be independent of each other, thus 
suggesting an increase in one difficulty would not predict the level of another.  Interestingly, 
irritability correlated positively with bad temper in the HD group while there was no 
correlation in the AD group.  Thus, while there was no significant difference between the two 
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groups, people with HD demonstrated higher levels of aggression and bad temper than those 
with AD.       
In addition, Litvan, Paulsen, Mega and Cummings (1998) compared people with HD 
to people with Progressive Supranuclear Palsy (PSP) using the NPI.  Irritability was shown to 
influence the total NPI score in people with HD.  Additionally, the HD group scored 
significantly higher on agitation, irritability and anxiety while those with PSP scored higher 
for apathy.  In the HD group agitation was positively correlated with anxiety, irritability, 
disinhibition and euphoria.  Similarly, irritability was associated with anxiety, disinhibition, 
euphoria and depression.  On comparing the two groups, logistic regression analysis indicated 
that people with HD were more likely to exhibit hyperactive behaviour (agitation, irritability) 
whereas people with PSP were more likely to exhibit hypoactive behaviour (apathy).  These 
findings support the earlier findings of Burns et al. (1990) which reported that irritability and 
apathy can occur independently of each other.  Correspondingly, the development of more 
recent measures such as the PBA-HD and results of factor analyses (Craufurd et al., 2001; 
Rickards et al., 2011) support the notion that irritability is a distinct independent difficulty 
experienced by people with HD.  
Association with other psychological difficulties  
Research into irritability has also often been investigated along with other 
psychological difficulties reported to be common in HD.  In light of findings comparing 
people with HD with other neurological conditions suggesting two independent processes, it 
seems necessary to examine this in more detail.  In order to examine the associations between 
irritability and other psychological difficulties, correlations were examined.  Of the twelve 
studies comparing irritability with other psychological difficulties in HD, eight reported 
correlations between irritability and other psychological difficulties.  Seven of these studies 
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reported significantly positive correlations with other psychological difficulties including 
apathy (Bouwens et al., 2015; Pflanz et al., 1991), anxiety (Litvan et al., 1998; Nimmagadda 
et al., 2011; Paulsen, Ready, Hamilton, Mega & Cummings, 2001), depression (Litvan et al., 
1998; Nimmagadda et al., 2011; van Duijn et al., 2014) and bad temper (Burns et al., 1990).  
Only one paper reported no correlation between irritability and cognitive impairment 
(Thompson et al., 2002). 
In addition, one paper found irritability was significantly positively correlated with 
suicidal ideation at baseline (Hubers et al., 2013) however this was not maintained at four-
year follow up and thus was not an independent predictor of suicidal ideation.  Furthermore, 
Banaszkiewicz et al. (2012) found irritability was not significantly related to functional 
disability.   
However, Bouwens et al. (2015), in a longitudinal analysis, demonstrated that an 
increase in irritability was associated with an increase in apathy over a two-year period, an 
association that was maintained after other variables had been controlled for.  Subsequently it 
was suggested that while irritability is often linked to the outward expression of anger, 
irritability may also only be expressed internally (Bouwens et al., 2015), similar to the 
proposition by Snaith and Taylor (1985) who developed the IDA to examine both inward and 
outward irritability.  Therefore, for some people with HD, irritability may be expressed 
inwardly and, as such, be experienced in a similar way to apathy.  Consequently, apathy has 
the potential to mask irritability whereby an individual may be internally distressed by 
feelings of irritability, without it being expressed overtly. 
 Furthermore, three studies found associations between irritability and anxiety.  Both 
Litvan et al. (1998) and Paulsen et al. (2001) found irritability to be significantly positively 
correlated with anxiety, r = 0.88 and r = 0.43 respectively, as measured by the NPI.  
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Similarly, Nimmagadda et al. (2011) also found that participants’ inward and outward 
irritability scores were both significantly positively associated with both their state and trait 
anxiety as measured by the IDA and STAI.  These correlations suggested the more anxiety a 
person felt, the more irritable they felt.  While the causal relationship cannot be determined 
here, it may be suggested that irritability can occur as a result of or in response to feelings of 
anxiety.  Therefore, people with HD who have higher levels of anxiety may be more prone to 
become irritable.  Alternatively, a high correlation such as that found by Litvan et al. (1998) 
may evidence that anxiety and irritability are the same construct.        
 In addition to apathy and anxiety, there were also associations between irritability and 
depression.  Irritability was found to be positively correlated with depression in the study by 
Litvan et al. (1998) using the NPI.  Additionally, Nimmagadda et al. (2011) also found 
irritability (both IDA-inward and IDA-outward) to be significantly positively associated with 
depression as measured subjectively by the IDA-D and objectively by the MADRS.  
However, these correlations did not persist when irritability was informant reported as 
measured by the BIS.  Nimmagadda et al. (2011) did however note that this difference could 
be due to informants not recognising irritability in people with HD struggling with 
depression.  This idea would be supported by the finding that the IDA-inward irritability 
score showed a stronger correlation with the depression score on the MADRS, suggesting 
people with depression in HD may internalise irritability and thus hide it from those around 
them.  Interestingly, evidence suggests that a history of depression (van Duijn et al., 2014) 
and bad temper (Burns et al., 1990) may increase the likelihood of people with HD 
experiencing irritability.     
 Treatment options for irritability in HD 
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 Additionally, it is also important to examine whether irritability can be improved in 
people with HD.  Three papers looked at the treatment options for irritability in HD 
(Bouwens et al., 2015; Groves et al., 2011; van Duijn, 2010).  Groves et al. (2011) examined 
the treatment of irritability in HD using an HD irritability survey developed for their research.  
Indeed, the evidence should be understood in the context in which it was gathered, i.e. by 
expert opinion rather than through a randomised control trial (RCT), and is therefore a lower 
level of evidence.  However, their survey revealed the use of a variety of pharmacological 
treatments used to reduce irritability without any general consensus, particularly with regards 
to treatment duration.  However, there was some consensus provided by expert clinicians 
with selective serotonin reuptake inhibitors (SSRIs) and antipsychotics (APDs) being the 
preferred medication.  Additionally, when considering that people with HD may also 
experience other psychological difficulties, as discussed above, there were differences in the 
selection of medication based on comorbidity.  SSRIs were preferred when irritability 
occurred with comorbid depression and anxiety whereas APDs were often used when 
irritability occurred alongside aggression and impulsivity (Groves et al., 2011).   
 As such it may be suggested that SSRIs are used more when irritability co-occurs with 
depression and APDs when irritability co-occurs with aggression.  Indeed, given the 
difference in usage by clinicians, it is possible that the medication used may actually be 
having an effect on the comorbid psychological difficulty i.e. depression, as opposed to 
irritability.  Considering the correlations with other psychological difficulties it is possible 
that this is the case and as such the treatment of these co-occurring difficulties is more 
effective than aiming to manage the irritability.  Consequently, it could be suggested that 
irritability occurs as part of these other difficulties, i.e. depression and anxiety, and as such 
does not represent a valid individual ‘symptom’ of HD.       
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 Interestingly, Bouwens et al. (2015), in a longitudinal study, found that the use of 
APDs was associated with an increase in irritability over a two-year period.  However, it 
cannot be ruled out that APDs were initially used due to the presenting level of irritability as 
opposed to increasing it.  Indeed, this would concur with the evidence suggesting APDs are 
the preferred choice of medication when anxiety co-occurs alongside aggression (Groves et 
al., 2011).   
Suggested neurological pathways for irritability in HD 
 Research has also examined the potential neurological pathways due to the little that 
is known about the potential brain changes associated with the psychological aspects of HD.  
Three studies included in this review investigated the underlying brain changes occurring in 
HD (Gregory et al., 2015; Kloppel et al., 2010; van den Stock et al., 2015).   
 Van den Stock et al. (2015) found evidence of striatal atrophy and increased 
irritability in the gene positive group compared to healthy controls.  They looked at the 
association between clinical irritability and experience of anger by correlating irritability 
scores on the PBA-HD with functional MRI (fMRI) activation in people who were gene 
positive, however not showing any motor symptoms. They found a significant positive 
correlation between irritability and pulvinar activation concluding that the thalamic pulvinar 
plays a key role in irritability in HD. Additionally, anger experience was associated with 
hyper-activation of the emotion experience neurocircuitry.  Therefore, it is possible that the 
areas of the brain assumed to be activated as a result of experiencing irritability may instead 
be activated by the experience of anger.       
 Kloppel et al. (2010) found higher levels of reported irritation were associated with 
stronger activation of the amygdala in controls compared with pre-symptomatic gene carriers 
for whom correlations were absent.  They argue that inappropriate responses of the amygdala 
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make pre-symptomatic gene carriers increasingly prone to psychological difficulties such as 
irritability.  Additionally, the involvement of the amygdala has also been found in research 
investigating aggression, highlighting a potential link for the experience of negative emotions 
such as irritability, anger and frustration more generally as opposed to being specific to 
irritability.   
 Furthermore, comparing people with early HD with people with pre-manifest HD, 
Gregory et al., (2015) found a significant negative correlation between irritability, as 
measured by the PBA-HD, and fractional anisotropy across the whole brain with a decrease 
in white matter microstructure.  These findings were reversed in those closer to onset with 
results being maintained following controlling for medication use.  Additionally, they 
suggested that due to the dominant involvement of the posterior tracts and left hemisphere it 
is possible that the increase in irritability could be a result of cognitive overload.  
Consequently, the evidence regarding the potential neural pathways seems unclear and 
potentially confounded by other psychological and cognitive aspects.     
Discussion 
Following the review of research looking at irritability in HD, the validity of 
irritability as a symptom in HD can now be assessed in terms of whether this is supported by 
the research.   
Considering that there is no gold standard for measuring irritability, cut off scores 
used across research often vary and, as such, remain arbitrary (Reedeker et al., 2012).  For 
example, three studies using the irritability scale (Chatterjee et al., 2005; Kloppel et al., 2010; 
Reedeker et al., 2012) used varying cut off scores of >15 and >14.  Although the variation in 
these is not great, there remains the potential for different results to be obtained.  While 
efforts have been made to reduce the impact of this on results, it seems that if irritability is to 
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be considered a symptom of HD, there should be standardised measures and scores specific 
for people with HD.  However, difficulties with agreement regarding standardised measures 
and clinical cut off scores seems to be perpetuated by the, still, lack of agreed definition.      
Additionally, as a result of this lack of agreed definition, it has been acknowledged 
that individual participants may have different understandings of irritability (Kloppel et al., 
2010).  Therefore, people’s experience and understanding of what irritability comprises is 
likely to differ as people attribute different behaviours to irritability.  For example, some 
people with HD may understand anger and aggression as a consequence of irritability 
whereas others may not.   
Indeed, it seems apparent that it is difficult to determine whether irritability is a 
separate construct from those such as anger, aggression and agitation.  For example, Paulsen 
et al. (2001) found a high correlation between irritability and agitation (r = 0.81) suggesting 
the same construct was being measured and as such irritability may not, as it is currently, be a 
valid independent symptom of HD.  This difficulty in discriminating between irritability and 
anger does not seem surprising when measurement is taken into account.  For example, the 
NPI was used in a number of studies in the current review (Litvan et al., 1998; Paulsen et al., 
2001), in which the item for irritability is ‘does the patient have sudden flashes of anger’ 
(Cummings et al., 1994).  As such, in the study by Paulsen et al. (2001) a positive correlation 
between agitation and irritability may be expected as a result of the measure used to assess 
irritability.  Siemer’s (2009) dispositional theory of moods assumes that moods dispose 
people to appraise events/situations in an emotionally congruent manner.  It may therefore be 
suggested that irritability may predispose an individual to become angry or make angry 
appraisals, consistent with how they are currently feeling.  
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Additionally, irritability has been shown to positively correlate with anxiety (Litvan et 
al., 1998; Paulsen et al., 2001) and depression (Litvan et al., 1998; Nimmagadda et al., 2011).  
The findings indicate the potential for irritability to result from feelings of anxiety and 
depression or vice versa as opposed to it being an independent construct.  Certainly it has 
been suggested, in irritability research in young people, that higher levels of irritability 
predict aggression, anxiety and depression in early adulthood (Leibenluft & Stoddard, 2013).     
Interestingly, a factor analysis showed irritability to be an independent factor 
(Craufurd et al., 2001).  However, aggression was located within this factor which may 
suggest these two constructs are not independent and that aggression occurs as part of 
irritability, potentially as an external expression.  Furthermore, irritability has been noted to 
be “viewed as a decreased threshold for experiencing frustration” (Deveney et al., 2013, 
p.1187).  As irritability is often elicited through tasks which induce frustration, it is possible 
that irritability is the expression of multiple frustrations which are likely to differ between 
people.  Subsequently, irritability may be the result of people struggling to regulate their 
emotions and behavioural responses, whereby if frustrations become too much, anger and 
aggression follows.   
Additionally, from the research reviewed here, the concept of irritability does not 
seem to have predictive validity.  Of the ten papers that investigated irritability across disease 
stage, seven did not find a difference suggesting irritability is not part of the disease process.  
Similarly, in those that did find a difference across disease stage, this was only found for the 
earlier disease stages.  Therefore, irritability did not follow the course of degeneration, while 
difficulties such as apathy did (Kingma et al., 2008).  Consequently, irritability may not be a 
valid predictor of a person’s experience of HD or the impact HD has on a person.  
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Indeed, this review has highlighted the variation in assessment tools and clinical cut 
offs used to assess irritability in HD.  As such, it may be suggested that irritability is unlikely 
to be consistently measured.  Considering the differences used in practice and research, 
where one person may be assessed as being ‘irritable’ by one measure, they may not be by 
another.  Consequently, it seems that irritability needs clear definition.  Considering the 
experience of irritability may differ in the context of HD, it is possible that irritability needs 
to be understood and defined specific to this clinical population.   
Additionally, assessing psychological difficulties in HD may be difficult as a result of 
the co-occurrence of physical, motor and cognitive difficulties (van Duijn et al., 2014).  
Consequently, consideration needs to be given to confounding factors which may contribute 
to a person’s experience of irritability to determine what the most appropriate form of support 
may be.  For example, treating irritability in HD in the same way as in the general population 
or different clinical populations may not be effective if confounding factors, potentially 
impacting on a person’s level of irritability, are ignored.   
Limitations and future research 
 This review, however, does have limitations.  Firstly, the review only included articles 
that were published in English.  Secondly, due to the broad nature of a scoping review, and 
the lack of a specific question to be answered, a general overview of the literature regarding 
irritability in HD is presented.  Consequently, more specific systematic reviews may be 
required in order to understand the various aspects of irritability in HD in more depth.  
 Future research needs to consider how irritability is understood in the context of HD.  
This may include further investigation into the neural pathways and circuitry associated with 
irritability and considering whether areas are, in fact, central to irritability or other potentially 
associated constructs such as anger.  Furthermore, consensus should be sought regarding the 
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measures used to assess irritability in HD, considering whether different measures do assess 
the same construct or variations of it.     
Conclusions 
Considering the available literature, there is currently no one satisfactory definition of 
irritability within the context of HD.  Indeed, considering the correlates of irritability, 
including depression, apathy and anxiety, it may be suggested that these may provide more 
meaningful information about a person’s experience.  Additionally, current treatment options, 
again appear designed to treat the comorbid psychological difficulties people experience 
rather than specifically targeting irritability.  Furthermore, with regards to understanding the 
aetiology of irritability in HD, the research remains unclear both in terms of the biological 
nature and aetiology of irritability and the associations with other psychological difficulties 
that co-occur.  Irritability may have cognitions associated with how a person feels when 
irritable which may subsequently lead to the overt expression of irritability as anger.  
Therefore, measures need to capture the associated behavioural, cognitive and affective 
dimensions (Eckhardt, Norlander & Deffenbacher, 2004).   
Indeed, the evidence presented makes it difficult to conclude whether irritability in 
HD is a valid concept, with conflicting results being found.  Certainly, some research has 
shown irritability to have convergent validity (Litvan et al., 1998; Paulsen et al., 2001) while 
other research has indicated that irritability discriminates from other constructs (Craufurd et 
al., 2001; Rickards et al., 2011).  Consequently, further research is required in order to fully 
understand the impact irritability has on quality of life in people with HD to conclude that it 
is a clinically meaningful symptom.    
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Table 1 
Summary of studies of irritability in HD  
Citation Participants (N) Gender (N) Age 
(Mean) 




et al. (2012) 
HD patient-
caregiver dyads (80) 
- 47.7 - UHDRS-b HAM-D 
Berrios et al. 
(2001) 
HD (26) Female (10) 
Male (16) 
37.8 People with HD IRR PER, BDI, CFQ, 
SIGNAL, MOC, DIS, 
STAI & STAI2 
Berrios et al. 
(2002) 
Gene carriers (32) 
Non carriers (66) 
Female (56) 
Male (42) 
46.7 Asymptomatic  IRR PER, BDI, CFQ, 
SIGNAL, MOC, DIS 














Burns et al. 
(1990) 

























Craufurd et al. 
(2001) 
Gene carriers (134) Female (71) 
Male (63) 
50 Various UHDRS, PBA-
HD 
 
Gregory et al 
(2015) 





46 Pre-symptomatic (39) 
Early symptomatic (45) 
PBA HADS 
Groves et al. 
(2011) 
Physician leaders 
from HD (55) 
speciality centres 
- - - - - 
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(55) 
Hubers et al. 
(2013) 
Gene carriers (2106 





50.3 Motor symptomatic  UHDRS-b - 
Julien et al. 
(2007) 
Gene carriers (89) 
Non carriers (115) 
Female (123) 
Male (81) 
38 - CIDI - 
Kingma et al. 
(2008) 
Non-carriers (56) 




45.3 Pre-symptomatic gene 
carriers (55) 






Kirkwood et al. 
(2002a) 










Kirkwood et al. 
(2002b)                                           
HD (175) 
Non carriers (363)   
Female (384) 
Male (154) 
41.4 Pre-symptomatic (149) 





of MMPI items) 
- 
Kloppel et al. 
(2010) 
Gene carriers (16) 


















- 43.8 (HD)  
66.6 (PSP) 
Various stages NPI UHDRS 
Nimmagadda 
et al. (2011) 
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45.5 Various NPI UHDRS 














Reedeker et al. 
(2012) 
Gene carriers (130)  
Non carriers (43) 
Informants (158) 





Rickards et al. 
(2010) 
People with HD 
(1690) 
- - - UHDRS-b - 
Thompson et 
al. (2002) 















48 Clinically diagnosed 
HD 
PBA-HD - 
Van den Stock 
et al. (2015) 
Gene carriers (20)  
Non carriers (20)  
Female (23) 
Male (17) 





Review of treatment 
studies 
- - - - - 
Van Duijn et 
al. (2013) 
HD (121) - - Pre-symptomatic = 46 
Symptomatic = 75 
PBA - 
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Note:   AD = Alzheimer’s disease; BADS = Behavioural Assessment of Dysexecutive Syndrome; BDI = Beck Depression Inventory; DIS = 
Dissociation Questionnaire; CFQ = Cognitive Failures Questionnaire; CIDI = Composite International Diagnostic Interview; HAM-D = 
Hamilton Depression Rating Scale; HDHQ = Hostility & Direction of Hostility Questionnaire; IRR = Snaith’s Irritability Scale; IS = Irritability 
Scale; MADRS = Montgomery & Asberg Depression Rating Scale; MMPI = Minnesota Multiphasic Personality Inventory; MMSE = Mini-
Mental State Exam; MOC = Maudsley Obsessive-Compulsive Questionnaire; NPI = Neuropsychiatric Inventory; PBA = Problem Behaviours 
Assessment; PER = Personality Deviance Scale; SIGNAL = Signal Detection Memory Test; SIS = Snaith Irritability Self-Assessment Scale; 
STAI & STAI2 = Spielberger Anxiety scales; UHDRS = Unified Huntington’s Disease Rating Scale 
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Table 2 
Results of studies of irritability in HD 
Citation Aim Results 
Banaszkiewicz 
et al. (2012) 
To identify determinants of 
quality of life, functional 
disability and caregiver 
burden.  
Irritability is not significantly associated with disability.  
Berrios et al. 
(2001) 
To investigate the 
relationship between 
psychiatric profile and CAG 
repeats.  
Compared with available norms, participants showed increased levels of ‘outward 
irritability’. No significant correlation with irritability and CAG repeat length.  
Berrios et al. 
(2002) 
To compare psychiatric 
profiles of gene carriers and 
non-carriers.   
Significant difference in inward and outward irritability between GC and NC, with irritability 
being higher in GC.  Factor structure: inward and outward irritability were included within 
the ‘personality’ factor.  
Bouwens et al. 
(2015) 
To investigate the course and 
temporal relationship 
between irritability and other 
psychological difficulties.   
No significant increase in irritability from baseline to follow-up. At baseline 33% of people 
with HD were irritable, with 70% of those remaining irritable at 2-year follow-up. Of those 
who were not irritable at baseline 23% developed irritability at 2-year follow-up. 
Multivariate regression model showed an association between increase in apathy and an 
increase in irritability. Continuous use of antipsychotics associated with an increase in 
irritability.  
Burns et al. 
(1990) 
To compare irritability, 
aggression and apathy in 
people with HD with people 
with AD.  
No significant difference in irritability or apathy between the HD and AD groups. HD group 
were significantly more aggressive than the AD group and aggressive outbursts lasted longer 
in the HD group.  Irritability, apathy & aggression were independent of each other in both 
groups. Irritability correlated positively with bad temper in the HD group but there was no 
correlation in the AD group.     
Chatterjee et al. 
(2005) 
To examine agreement 
between people with HD and 
their caregivers regarding 
presence of irritability, 
apathy and depression.  
No significant difference in report of irritability between PwHD and caregivers. No 
difference in BDI scores. Difference in apathy scores between the two groups.   
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Craufurd et al. 
(2001) 
To understand behavioural 
abnormalities in HD and 
develop a method of 
assessing these changes.  
Irritability present in 44% of sample (severity rating of 2 or more). Three factors obtained 
from factor analysis: 1 - apathy; 2 - irritability; 3 - depression.  Irritability difficulties 
occurred more frequently in people with HD with an illness duration of 6-11 years.  
Irritability factor showed no correlation with duration of illness or CAG repeat length.  
Gregory et al 
(2015) 
Investigate structural 
connectivity and changes 
associated with depression, 
apathy and irritability in HD.  
Significant difference in irritability between the two groups. Significant negative correlations 
between irritability score and fractional anisotropy which was dependent on cumulative 
probability to onset.  
Groves et al. 
(2011) 
To provide direction for the 
management of irritability in 
HD. 
SSRIs were most frequently used to treat mild to moderate irritability in HD. Antipsychotics 
(APD) were more commonly used in Europe to treat mild to moderate irritability than in 
North America & Australia.  SSRIs used when irritability occurred with comorbid depression 
and anxiety. APDs used when irritability occurred with aggression and impulsivity.  
Hubers et al. 
(2013) 
To investigates predictors 
and correlates of suicidal 
ideation in HD.  
Baseline presence of irritability significantly correlated with suicidal ideation – those with 
suicidal ideation were more irritable than those without. Multivariate analyses indicated 
irritability was not an independent correlate of suicidal ideation. At follow-up, irritability was 
not a predictor of suicidal ideation in HD. 
Julien et al. 
(2007) 
To compare the prevalence of 
psychological difficulties in 
pre-symptomatic gene 
carriers and non-carriers and 
to look at the relationship 
with proximity to onset.  
Gene carriers reported a greater prevalence of ‘manic’ symptoms (11%) compared with NGC 
(4%) – in every case irritability was reported. Irritability was increased in gene carriers up to 
10 years prior to clinical onset but not in those further from onset. No significant relationship 
between proximity to onset and irritability within the 10 year period.     
Kingma et al. 
(2008) 
To investigate the 
behavioural difficulties in 
HD.  
Factor analysis revealed 3 components: irritability, apathy and depression. All mutation 
carriers showed significantly more irritability, apathy & depression than non-carriers. No 
significant difference in irritability between ASGC and other disease stages. No significant 
relationship between irritability and depression or apathy.   
Kirkwood et al. 
(2002a) 
To examine whether 
longitudinal changes in 
personality can be detected in 
pre-symptomatic gene 
carriers. 
Greater increase irritability and clinical hostility observed over time in the PSGC group 
compared with NGC.  No correlation between number of CAG repeats and irritability in both 
groups.   
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Kirkwood et al. 
(2002b)                                                 
To investigate whether 
psychological difficulties can 
be detected in pre-
symptomatic HD.  
No significant difference in MMPI scores across groups. No significant difference in 
irritability across the three groups and no association with proximity to onset.  
Kloppel et al. 
(2010) 
To examine the emotional 
neurocircuitry associated 
with irritation,  
No significant difference in irritability between PSC and controls.  Companions ratings did 
not differ from those of the PSC.  Ratings on the SIS were within normal range apart from 1 
PSC.  Negative emotions positively correlated with SIS & BIS-11.   
Litvan et al. 
(1998) 
To compare neuropsychiatric 
aspects of HD compared with 
PSP.  
Irritability influenced the total NPI score in PwHD. PwHD scored significantly higher on 
agitation, irritability and anxiety while those with PSP scored higher for apathy.  In PwHD, 
agitation was correlated with anxiety, irritability, disinhibition and euphoria.  Irritability was 
associated with anxiety, disinhibition, euphoria and depression. Logistic regression analysis 
indicated PwHD are more likely to exhibit hyperactive behaviour. People with PSP are more 
likely to exhibit hypoactive behaviour.     
Nimmagadda et 
al. (2011) 
To investigate the association 
of irritability in HD with 
other psychological 
constructs and movement 
disorder.  
Both inward and outward irritability were significantly positively associated with MADRS 
scores, STAI state and trait anxiety scores. BIS scores were positively associated with STAI 
trait scores and both outward and inward irritability scores on the IDA. Negative correlation 
between irritability scores and the UHDRS.  
 
Paulsen et al. 
(2001) 
To use the NPI to 
characterise neuropsychiatric 
symptoms in HD.  
Irritability endorsed in 65.4% of sample. NPI - High correlation between irritability & 
agitation indicating two scales are measuring the same construct. Irritability also correlated 
with anxiety and disinhibition.  
Pflanz et al. 
(1991) 
To determine the range and 
frequency of psychological 
difficulties in HD.  
Irritability present in 64% of cases and was the 2nd most common difficulty. Irritability 
occurred between 0-3 years prior to onset of motor symptoms.  Loss of interest and 
concentration correlated with irritability.   
Reedeker et al. 
(2012) 
To investigate the 
psychometric properties of 
the Irritability Scale against 
the PBA irritability factor to 
establish a reliable cut off.  
Irritability significantly higher in MC (35% irritable) than NC (9% irritable). 28% of MC 
considered irritable according to IS-self and informant scales. 50% considered not irritable 
according to both scales. For the remaining 23% there was disagreement between 
participants and informants (18/27 reported selves as not irritable but their informant did). 
Irritability independently correlated with benzodiazepine use.  
Rickards et al. 
(2010) 
To perform a factor analysis 
on completed UHDRS-b 
Factor analysis indicated that irritability is a distinct ‘psychiatric symptom’ in HD.  
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assessments.   
Thompson et al. 
(2002) 
To investigate how 
behavioural change in HD 
relates to other indices of 
disease severity. 
Depression & irritability subscales poorly correlated with functional capacity, motor 
impairment & cognition. Apathy was significantly correlated. UHDRS-b score significantly 
correlated with PBA-HD depression & irritability subscales.  UHDRS irritability scale 
significantly correlated with irritability subscale of the PBA-HD.   
Thompson et al. 
(2012) 
To evaluate the prevalence of 
neuropsychiatric difficulties 
in HD over time.  
Irritability common with a prevalence ranging from 49-83%. Longitudinal analysis showed 
an increase in irritability over time with a significant linear effect in those who entered the 
study at stage I and II but not in those who entered at stage III of HD.  
Van den Stock 
et al. (2015) 
Identify structural and 
functional brain changes 
underlying irritability in pre-
manifest HD.  
Irritability significantly higher in GC vs NC. 
Van Duijn. 
(2010) 
To review the treatments of 
irritability.  
Suggests use of an SSRI as a first choice medication to manage irritability in HD or a mood 
stabiliser.  An alternative would be an antipsychotic. Behavioural or other psychotherapeutic 
interventions should be considered.    
Van Duijn et al. 
(2013) 
To investigate the 
progression of irritability, 
depression and apathy in HD 
over a 2-year follow up.  
2-year follow-up: No significant change in irritability.  Associations between PBA factor 
scores and UHDRS-m: as UHDRS-m score increased so did the PBA irritability factor. In 
pre-symptomatic group, strongest relationship was between an increased UHDRS-m score 
and increased irritability score.  At follow-up 15 of the pre-symptomatic group were 
symptomatic. No significant increase in irritability compared with those who remained pre-
symptomatic.  
Van Duijn et al. 
(2014) 
To examine the occurrence 
and correlates of 
neuropsychiatric symptoms 
in HD. 
61.4% of HD mutation carriers scored ‘no irritability’, 24.7% scored ‘mild irritability’ and 
13.9% scored ‘moderate/severe irritability’. The prevalence of moderate/ severe irritability 
increased by stage of disease from 10.4% at stage 1 to 19.6% at stages 4-5.  Irritability 
independently correlated with male sex, younger age, a history of depression, psychosis and a 





To distinguish which 
behavioural and psychiatric 
features differentiate gene 
carriers with non-carriers.   
No significant difference in irritability between GC and NC. Higher extroverted hostility in 
GC than in NC. Overlap between the two groups suggests extroverted hostility may not be 
pathologic in GC. 
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Table 3  
Measures of irritability in HD 
Measure Description Reliability Validity 
Burns Irritability Scale 
(BIS; Burns, Folstein, 
Brandt & Folstein, 1990) 
Measures irritability and 
apathy according to carer’s 
ratings and does not 
include subjective 
experience. It uses a 5-
point scale assessing the 
presence of irritability 
ranging from “never” to 
“always”.  
Internal consistency: 
- Irritability: α = 0.82 
- Apathy: α = 0.78 
Inter-rater1: 
- Whole interview: κ = 0.98 
- Irritability: κ = 1.00 
- Apathy: κ = 0.85 
Test-retest: 
- Whole interview: κ = 0.88 
- Irritability: κ = 0.81 
- Apathy: κ = 0.76 
Convergent: 
- Psychogeriatric 
Dependency Rating Scale: r 
= 0.87 
Irritability, depression, 
anxiety scale (IDA; Snaith, 
Constantopoulos, Jardine & 
McGuffin 1978) 
Scale assessing irritability, 
depression and anxiety to 
be used within clinical 
context.  Irritability 
understood as a temporary 
psychological state. 
Includes 8 irritability items 
Inter-rater: 
- Outward irritability: r = .87-.90 
- Inward irritability: r = .74-.90 
- Depression: r = .80-.90 
- Anxiety: r = .75-.80 
Split-half:  
- Outward irritability: r = .77, 
.80, .88 
- Inward irritability: r = .70, .92, 
.93 
- Depression: r = .72, .77, .81 
- Anxiety: r = .74, .80, .87 
 
Irritability Questionnaire 
(IRQ; Craig, Hietenan, 
Subjective measure of 
irritability. Consists of 21 
Internal consistency: 
- Global: α = 0.90 
Convergent: 
- Trait anger scale: r = 0.72 
                                                          
1 Looked at the presence or absence of irritability. 
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Markova & Berrios, 2008) items assessing the 
frequency and severity of 
irritability with each 
individual item score 
ranging from 0-3.   
             Split half = 0.78 
- Frequency: α = 0.90 
                   Split half = 0.77 
- Severity: α = 0.89 
                Split half = 0.58 
Retest reliability: r = 0.82 
- State anger scale: r = 0.58 
- IDA outward: r = 0.58 
- IDA inward: r = 0.49 
- BIS: r = 0.37 
  
John Hopkins Irritability 
Scale (Chattergee, 
Anderson, Moskoqitz, 
Hauser & Marder, 2005) 
Objective measure 
(informant-report) of 
irritability.  Consists of 14 
items pertaining to 
irritability with the range 
of all possible scores being 
0-42 to assess the presence 
of irritability.  
No data available No data available 
Problem Behaviours 
Assessment – Huntington’s 
disease (PBA-HD; 




difficulties in HD 
including the presence, 
severity and frequency.  
Inter-rater:  
- Severity: r = 0.86 
- Frequency: r = 0.84 
Internal consistency: α = 0.67 
Test-retest:  
- Severity: r = 0.94 
- Frequency: r = 0.92 
 
Unified Huntington’s 
Disease Rating Scale 
(UHDRS; Huntington 
Study Group, 1996) 
Assesses difficulties in 
motor, cognitive, 
functional and behavioural 
domains.  The behavioural 
section measures the 
frequency and severity of 
difficulties related to 
affect, thought content and 
coping styles. 
Internal Consistency: 
- Behavioural: α = 0.83 
- Motor: α = 0.95 
- Cognitive: α = 0.90 
- Functional: α = 0.95 
Divergent (Behavioural Total): 
- Motor: r = -0.10 
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Appendix 1-A: Author Guidelines  
 
British Journal of Health Psychology 
Author Guidelines 
 
The aim of the British Journal of Health Psychology is to provide a forum for high quality research 
relating to health and illness. The scope of the journal includes all areas of health psychology as 
outlined in the Journal Overview. 
The types of paper invited are:  
• papers reporting original empirical investigations, using either quantitative or qualitative methods, 
including reports of interventions in clinical and non-clinical populations;  
• theoretical papers which may be analyses or commentaries on established theories in health 
psychology, or presentations of theoretical innovations;  
• we particularly welcome review papers, which should aim to provide systematic overviews, 
evaluations and interpretations of research in a given field of health psychology; and  
• methodological papers dealing with methodological issues of particular relevance to health 
psychology. 
 
All papers published in The British Journal of Health Psychology are eligible for Panel A: Psychology, 
Psychiatry and Neuroscience in the Research Excellence Framework (REF). 
1. Circulation 
The circulation of the Journal is worldwide. Papers are invited and encouraged from authors 
throughout the world.  
2. Length 
Papers should normally be no more than 5000 words (excluding the abstract, reference list, tables 
and figures), although the Editor retains discretion to publish papers beyond this length in cases 
where the clear and concise expression of the scientific content requires greater length.  
3. Editorial policy 
The Journal receives a large volume of papers to review each year, and in order to make the process 
as efficient as possible for authors and editors alike, all papers are initially examined by the Editors 
to ascertain whether the article is suitable for full peer review. In order to qualify for full review, 
papers must meet the following criteria:  
• the content of the paper falls within the scope of the Journal  
• the methods and/or sample size are appropriate for the questions being addressed  
• research with student populations is appropriately justified  
• the word count is within the stated limit for the Journal (i.e. 5000 words)  
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4. Submission and reviewing 
All manuscripts must be submitted via Editorial Manager. The Journal operates a policy of 
anonymous (double blind) peer review. We also operate a triage process in which submissions that 
are out of scope or otherwise inappropriate will be rejected by the editors without external peer 
review to avoid unnecessary delays. Before submitting, please read the terms and conditions of 
submission and the declaration of competing interests. You may also like to use the Submission 
Checklist to help your prepare your paper.  
5. Manuscript requirements 
• Contributions must be typed in double spacing with wide margins. All sheets must be numbered.  
• Manuscripts should be preceded by a title page which includes a full list of authors and their 
affiliations, as well as the corresponding author's contact details. A template can be downloaded 
from here.  
• For articles containing original scientific research, a structured abstract of up to 250 words should 
be included with the headings: Objectives, Design, Methods, Results, Conclusions. Review articles 
should use these headings: Purpose, Methods, Results, Conclusions. As the abstract is often the 
most widely visible part of your paper, it is important that it conveys succinctly all the most 
important features of your study. You can save words by writing short, direct sentences. Helpful 
hints about writing the conclusions to abstracts can be found here. 
• Statement of Contribution: All authors are required to provide a clear summary of ‘what is already 
known on this subject?’ and ‘what does this study add?’. Authors should identify existing research 
knowledge relating to the specific research question and give a summary of the new knowledge 
added by your study. Under each of these headings, please provide 2-3 (maximum) clear outcome 
statements (not process statements of what the paper does); the statements for 'what does this 
study add?' should be presented as bullet points of no more than 100 characters each. The 
Statement of Contribution should be a separate file.  
• Conflict of interest statement: We are now including a brief conflict of interest statement at the 
end of each accepted manuscript. You will be asked to provide information to generate this 
statement during the submission process.  
• The main document must be anonymous. Please do not mention the authors’ names or affiliations 
(including in the Method section) and always refer to any previous work in the third person.  
• Tables should be typed in double spacing, each on a separate page with a self-explanatory title. 
Tables should be comprehensible without reference to the text. They should be placed at the end of 
the manuscript but they must be mentioned in the text.  
• Figures can be included at the end of the document or attached as separate files, carefully labelled 
in initial capital/lower case lettering with symbols in a form consistent with text use. Unnecessary 
background patterns, lines and shading should be avoided. Captions should be listed on a separate 
sheet. The resolution of digital images must be at least 300 dpi. All figures must be mentioned in the 
text.  
• For reference citations, please use APA style. Particular care should be taken to ensure that 
references are accurate and complete. Give all journal titles in full and provide doi numbers where 
possible for journal articles. For example: 
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Author, A., Author, B., & Author, C. (1995). Title of book. City, Country: Publisher. 
Author, A. (2013). Title of journal article. Name of journal, 1, 1-16. doi: 10.1111/bjep.12031  
• SI units must be used for all measurements, rounded off to practical values if appropriate, with the 
imperial equivalent in parentheses.  
• In normal circumstances, effect size should be incorporated.  
• Authors are requested to avoid the use of sexist language.  
• Authors are responsible for acquiring written permission to publish lengthy quotations, 
illustrations, etc. for which they do not own copyright. For guidelines on editorial style, please 
consult the APA Publication Manual published by the American Psychological Association.  
• Manuscripts describing clinical trials are encouraged to submit in accordance with the CONSORT 
statement on reporting randomised controlled trials.  
• Manuscripts reporting systematic reviews and meta-analyses are encouraged to submit in 
accordance with the PRISMA statement.  
• Manuscripts reporting interventions are encouraged to describe them in accordance with the 
TIDieR checklist.  
6. Supporting information 
Supporting Information can be a useful way for an author to include important but ancillary 
information with the online version of an article. Examples of Supporting Information include 
appendices, additional tables, data sets, figures, movie files, audio clips, and other related 
nonessential multimedia files. Supporting Information should be cited within the article text, and a 
descriptive legend should be included. Please indicate clearly on submission which material is for 
online only publication. It is published as supplied by the author, and a proof is not made available 
prior to publication; for these reasons, authors should provide any Supporting Information in the 
desired final format.  
For further information on recommended file types and requirements for submission, please visit 
the Supporting Information page on Author Services.  
7. OnlineOpen 
OnlineOpen is available to authors of primary research articles who wish to make their article 
available to non-subscribers on publication, or whose funding agency requires grantees to archive 
the final version of their article. With OnlineOpen, the author, the author's funding agency, or the 
author's institution pays a fee to ensure that the article is made available to non-subscribers upon 
publication via Wiley Online Library, as well as deposited in the funding agency's preferred archive. A 
full list of terms and conditions is available on Wiley Online Library.  
Any authors wishing to send their paper OnlineOpen will be required to complete the payment form.  
Prior to acceptance there is no requirement to inform an Editorial Office that you intend to publish 
your paper OnlineOpen if you do not wish to. All OnlineOpen articles are treated in the same way as 
any other article. They go through the journal's standard peer-review process and will be accepted 
or rejected based on their own merit.  
8. Author Services 
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Author Services enables authors to track their article – once it has been accepted – through the 
production process to publication online and in print. Authors can check the status of their articles 
online and choose to receive automated e-mails at key stages of production. The author will receive 
an e-mail with a unique link that enables them to register and have their article automatically added 
to the system. You can then access Kudos through Author Services, which will help you to increase 
the impact of your research. Visit Author Services for more details on online production tracking and 
for a wealth of resources including FAQs and tips on article preparation, submission and more.  
9. Copyright and licences 
If your paper is accepted, the author identified as the formal corresponding author for the paper will 
receive an email prompting them to login into Author Services, where via the Wiley Author Licensing 
Service (WALS) they will be able to complete the licence agreement on behalf of all authors on the 
paper.  
For authors signing the copyright transfer agreement 
If the OnlineOpen option is not selected the corresponding author will be presented with the 
copyright transfer agreement (CTA) to sign. The terms and conditions of the CTA can be previewed in 
the samples associated with the Copyright FAQs .  
For authors choosing OnlineOpen 
If the OnlineOpen option is selected the corresponding author will have a choice of the following 
Creative Commons Licence Open Access Agreements (OAA): 
 
- Creative Commons Attribution Non-Commercial Licence (CC-BY-NC) 
- Creative Commons Attribution Non-Commercial -NoDerivs Licence (CC-BY-NC-ND)  
To preview the terms and conditions of these open access agreements please visit the Copyright 
FAQs and you may also like to visit the Wiley Open Access Copyright and Licence page.  
If you select the OnlineOpen option and your research is funded by The Wellcome Trust and 
members of the Research Councils UK (RCUK) or the Austrian Science Fund (FWF) you will be given 
the opportunity to publish your article under a CC-BY licence supporting you in complying with your 
Funder requirements. For more information on this policy and the Journal’s compliant self-archiving 
policy please visit our Funder Policy page.  
10. Colour illustrations 
Colour illustrations can be accepted for publication online. These would be reproduced in greyscale 
in the print version. If authors would like these figures to be reproduced in colour in print at their 
expense they should request this by completing a Colour Work Agreement form upon acceptance of 
the paper.  
11. Pre-submission English-language editing 
Authors for whom English is a second language may choose to have their manuscript professionally 
edited before submission to improve the English. A list of independent suppliers of editing services 
can be found in Author Services. All services are paid for and arranged by the author, and use of one 
of these services does not guarantee acceptance or preference for publication.  
12. The Later Stages 
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The corresponding author will receive an email alert containing a link to a web site. The proof can be 
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This will enable the file to be opened, read on screen and annotated direct in the PDF. Corrections 
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Abstract 
Aim: This study sought to investigate how people with Huntington’s disease (HD) 
understand and experience psychological distress in HD and their expectations of 
psychological therapy. 
Method:  A qualitative methodology was adopted involving semi-structured interviews and 
interpretative phenomenological analysis (IPA).  A total of nine participants (five women and 
four men) who had opted in to engage in a trial of mindfulness-based cognitive therapy 
(MBCT) were recruited and interviewed prior to the MBCT trial.  Interviews were 
transcribed verbatim and analysed using IPA whereby themes were analysed within and 
across transcripts and classified into superordinate themes. 
Results:  Three superordinate themes were developed:  Attributing psychological distress to 
HD: “you’re blaming everything on that now”; Changes across time: “in the past you’d just 
get on with it”; Therapy instils hope and fight: “a light at the end of the tunnel”. 
Conclusion: Understandings of psychological distress in HD ranged from biological to 
psychological explanations, with both often being accepted simultaneously by the same 
individual.  Individual experience seemed to reflect a dynamic process whereby people’s 
understanding and experience changed over time.  Psychological therapy was accepted as a 
positive alternative to medication, providing people with HD with hope that their 
psychological wellbeing could be enhanced.   
Keywords: Huntington’s disease; psychological difficulties; psychological therapy, 
mindfulness based cognitive therapy 
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Understandings of psychological difficulties in people with Huntington’s disease and their 
expectations of psychological therapy 
Huntington’s disease (HD) is a chronic neurodegenerative disease which causes 
problems with movement, coordination, cognitive functioning, and is often also associated 
with a number of different emotional difficulties.  It is suggested that around five to ten per 
100,000 people are affected (Kay, Fisher & Hayden, 2014) and as HD is a genetic disease 
with a 50% chance of inheriting the affected gene from a parent with HD, people with HD 
have often seen their parents affected by the disease (Kremer, 2002).  People are generally 
diagnosed between the ages of 35-55 years with a life expectancy of around 15-20 years after 
diagnosis (which is usually given upon the onset of motor symptoms; Keenan, Simpson, 
Miedzybrodzka, Alexander & Semper, 2013).  Considering the age at which people may be 
diagnosed with HD it may be reasonable to view this as a ‘disruptive event’ (Bury, 1982) in 
which people are required to re-evaluate the trajectory of their life and attempt to adjust 
accordingly. 
For people with a family history of HD, and who are subsequently at risk, predictive 
testing can be carried out prior to an individual showing any symptoms (Novak & Tabrizi, 
2010).  This will indicate whether or not a person will go on to develop HD in the future.  
Additionally, a diagnostic test is performed once a person presents with problems indicative 
of HD (Novak & Tabrizi, 2010).  It is important to consider the psychological and emotional 
implications attached to accessing these tests and the results, given that someone receiving a 
positive test will go on to develop HD (Meiser & Dunn, 2000).  For an individual who 
receives a positive predictive test, they are left knowing there is no cure but with the 
uncertainty of when and how the disease will begin to progress.  However, some people find 
this uncertainty more tolerable than the uncertainty of not knowing whether they have 
inherited the affected gene (Novak & Tabrizi, 2010). 
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People with HD often experience emotional difficulties.  The most common include 
depression, anxiety, apathy and irritability (Kirkwood, Su, Conneally & Foroud, 2001) and 
these have the potential to impact on quality of life, perhaps even more so than motor 
problems or cognitive impairment (Ho, Gilbert, Mason, Goodman & Barker, 2009).  It has 
been argued that difficulties with mood, such as depression, are often one of the earliest signs 
of HD preceding motor difficulties (Pla, Orvoen, Saudou, David & Humbert, 2014).  High 
levels of depression in HD, ranging from 33-69% (see van Duijn, Kingma & van Der Mast, 
2007 for review), have become expected as a result of the understanding it has a biological 
origin, the potential for cognitive impairment and the 50% risk of passing the gene on to 
children (Paulsen et al., 2005).  Moreover, depression is observed most often in HD when the 
HD starts to impact on an individual’s functional capacity and independence (Paulsen et al., 
2005).   
In addition, anxiety also co-occurs alongside depression.  In a systematic review, Dale 
and van Duijn (2015) found that anxiety was present in between 13% to 71% of people with 
manifest HD.  Additionally, there was no significant difference between people with manifest 
(presence of motor symtoms) and pre-manifest (confirmation of HD gene but motor symtoms 
currently absent) HD in levels of anxiety.  The presence of anxiety in HD may be a result of 
environmental stressors whereby people may become overwhelmed by their situation as well 
as tasks that may have previously required little attention (Hoffman,1999).  Indeed, elevated 
levels of anxiety were found to be present in those who were gene positive, both close to and 
far from onset (Duff, Paulsen, Beglinger, Langbehn & Stout, 2007).  
Furthermore, irritability is commonly reported in people with HD and has been shown 
to be present in up to 50 percent of people with HD (Craufurd, Thompson & Snowden, 2001; 
Dewhurst, Oliver, Trick & McNight, 1969).  Indeed, irritability, alongside anxiety and 
depression, is noted to be a core psychological feature of HD at the pre-symptomatic stage 
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(Kloppel et al., 2010); it is argued to cause significant distress, not only to the person with 
HD but to those around them such as family members and carers (Nimmagadda, Agrawal, 
Worrall-Davies, Markova & Rickards, 2011).  However, Kingma et al. (2008) found that 
depression and irritability are not linked to stage of disease with similar levels found in those 
at pre-, early and advanced stages indicating that people with HD may experience these for 
many years and subsequently need support throughout the progression of the disease.  
Similarly, Nimmagadda et al., (2011) suggested that irritability was related to the behavioural 
and affective difficulties in HD rather than the progressive motor and cognitive difficulties. 
The dominant perspectives within the HD field are to look for largely biological 
determinants of distress.  For example, many researchers take the view that psychological 
difficulties occur as a result of biological factors whereby neural mechanisms in the brain are 
affected by HD which then subsequently affect mood (Paulsen et al., 2005).  Indeed, 
Kowalski, Belcher, Keltner and Dowben (2015) summarised that depression, one of the most 
common psychological difficulties in HD, “appears to be a direct neurological consequence 
of the brain condition, rather than a psychological reaction to this serious illness” (p.159).   
However, psychological distress can also be understood from different perspectives 
within the broader field of chronic illness research and this is starting to influence how 
distress in HD can be understood.  For example, evidence suggests that psychological factors 
such as what people believe about the illness and coping strategies are also influential in 
predicting psychological distress and well-being in people with HD (Arran, Craufurd & 
Simpson, 2013; Kaptein et al., 2006).  A reaction to the onset of a disease such as HD may 
explain the occurrence of depression in HD (Pla et al., 2014).  Similarly, Julien et al. (2007) 
also proposed that difficulties such as depression are reactive and indicate an emotional 
response to the awareness of future motor impairment.       
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Perhaps not surprisingly given the dominance of biological accounts, medication such 
as anti-depressants are often used to manage psychological difficulties in HD (Craufurd & 
Snowden, 2011).  However, regardless of its efficacy, medication may not always be the 
preferred option for people with HD as they have to manage the potential side effects of 
medication (Aubeeluck & Wilson, 2008) and how this can impact on their own drug regimes.  
Consequently, psychological interventions may provide an alternative or additional way to 
reduce distress.   
Currently, little evidence exists of the acceptability and efficacy of psychological 
approaches for people with HD.  However, in another neurodegenerative disease, Parkinson’s 
disease (PD), there is increasing evidence to support the use of psychological interventions 
for low mood and anxiety in this population (see Charidimou, Seamons, Selai & Schrag, 
2011, for a review).  Such approaches include mindfulness-based cognitive therapy (MBCT; 
Fitzpatrick, Simpson & Smith, 2010) and cognitive behavioural therapy (CBT; Dobkin et al., 
2011).  However, currently no trial has been conducted evaluating a psychological therapy in 
people with HD.  Clearly, then it could be useful to assess whether psychological 
interventions are seen as potentially beneficial.     
As a result, this study adopted a qualitative methodology in order to obtain detailed 
accounts of people with HD’s understanding and experience of psychological difficulties and 
expectations of psychological therapy.  Given the dominance of biological accounts for 
psychological problems, at least within the scientific and clinical community, it was 
considered important to understand whether beliefs about cause of distress and the possibility 
of therapy would be consistent.  In order to address this, semi-structured interviews were 
conducted and analysed using interpretative phenomenological analysis (IPA; Smith & 
Osborn, 2003).  Due to the inductive nature of this analytic approach it was possible to gain 
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insight into the lived experiences of individuals and as such is appropriate to understand how 
people with HD perceive and experience psychological distress and psychological therapy.  
Consequently, this study aimed to investigate individuals with HD’s understanding of 
psychological difficulties in HD and their views of psychological therapy.  Participants were 
recruited from those due to take part in a trial of MBCT and therefore the study focused on 
people’s knowledge of psychological therapy, as well as their hopes and expectations of a 
psychological approach.         
Method 
Design 
The study employed a qualitative methodology to obtain participants’ understanding 
of psychological distress and the opportunities offered by psychological therapy in the 
context of HD.  IPA (Smith & Osborn 2003) was used to analyse the data.  IPA is widely 
used in psychological research and aims to explore how people understand and make sense of 
their experiences within their personal, and social world (Smith, Flowers & Larkin, 2009).     
Participants 
People with HD were eligible to take part.  Participants with HD were recruited from 
an ongoing MBCT trial (Clinicaltrials.gov: NCT02464293) of which a summary can be seen 
in Appendix 2-A.  To be included in the MBCT trial participants had to meet the following 
criteria: confirmed CAG expansion on the huntingtin gene; be a gene carrier and either be 
pre-symptomatic or at an early stage; have clinical signs of low mood or depression as 
identified in their clinical notes or other information recorded at their last clinic visit; be aged 
18 years or over; and have not had any changes in their medication six weeks prior to the start 
of the MBCT trial.  Participants were excluded if they had current active suicidal intent.   
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In the current study all participants were required to understand and be able to speak 
English and be aged 18 or over.  Nine participants, out of a potential 11, agreed to take part.  
All participants were people with the HD gene and pre-symptomatic (prior to the onset of 
motor symptoms), five of whom were female and four male.  Participants were aged between 
24-56 years with the time since receiving confirmation of the HD gene ranging from 1-17 
years.  Additionally, six participants were taking antidepressant medication and four 
participants had previous experience of psychological therapy.   
Recruitment 
Recruitment took place prior to participants commencing the MBCT course.  MBCT 
is an eight-week group therapy developed by Segal, Williams and Teasdale (2002) which 
teaches mindfulness skills through a range of practices with the aim of preventing the 
reoccurrence of depression (Gu, Strauss, Bond & Cavanagh, 2015).  Currently, MBCT is 
being piloted for individuals with HD with the aim of alleviating psychological distress.   
Potential participants were initially introduced to the research face to face via a 
member of the research team from the MBCT trial.  Participants were provided with a 
participant information pack which included a participant information sheet (see Ethics 
Appendix 4-4) and consent to contact form (see Ethics Appendix 4-5) with a cover letter (see 
Ethics Appendix 4-6).  Participants interested in taking part completed the consent to contact 
form during their initial meeting with the research team member for the MBCT trial.  They 
were then contacted, either by phone or email depending on their preferred method of 
contact, by the principal researcher to discuss the study and consider if they would like to 
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Data Collection 
Data were collected via interviews guided by a semi-structured interview schedule 
(see Ethics Appendix 4-2).  However, further questions were asked which were sensitive to, 
and guided by, the participants’ responses.  All interviews were completed during October 
2015.  All interviews were conducted face to face and at a non-NHS location at a time 
convenient for the participant.  Interviews lasted between 45 and 65 minutes, with an average 
duration of 54 minutes.  At the beginning of each interview the principal researcher checked 
that each participant had read the participant information sheet and went through the consent 
form (see Ethics Appendix 4-7), offering participants the chance to ask any questions prior to 
consenting to participate.  All participants signed the consent form to participate and have 
their interview audio recorded.   
Prior to commencing the interview, the principal researcher explained the concept of 
confidentiality, and its limits, to each participant and ensured they understood this.  At the 
end of each interview participants were debriefed and given time to ask any questions they 
had about the interview process and subsequent analysis and write up.  Each participant was 
given a pseudonym to retain their anonymity.            
Data analysis  
All interviews were transcribed verbatim by the principal researcher and all personal 
identifying information was removed.  The interview transcripts were analysed using IPA, 
following the stages outlined by Smith and Osborn (2003).  IPA enables themes to be drawn 
from the data to reflect the phenomenological understanding participants have of their 
experiences and the meaning they ascribe to these (Smith & Osborn, 2003).  For each 
participant, their transcript was read then re-read with interesting comments relevant to the 
research question being noted and used to develop emerging themes.  An extract of a 
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participant’s transcript with annotations and developing themes can be seen in Appendix 2-B.  
Following this, emerging themes were then clustered together based on their apparent 
similarities by copying the emerging themes into a table and giving each cluster a theme 
name.  This was done individually for each participant.  Once this was complete, super-
ordinante themes were developed which best fit participants’ experiences.    
Ethics  
The study was reviewed and approved by the National Research Ethics Service 
(NRES) and research governance approval obtained from the relevant hospital trust research 
and development department. 
Reflexivity 
In order to ensure the quality of the of qualitative research, principles such as 
sensitivity to context, rigour and transparency are important to consider (Yardley, 2000) and 
attempts were made, in both the methodology and reporting of results, to adhere to these 
principles.  The principal researcher attended the MBCT group which enabled a more in 
depth understanding of participants lives and as such the context in which they made sense of 
their experiences.  Additionally, as a result of attending the MBCT group a reflective diary 
was kept throughout the research to support the process of reflexivity and ensure the 
interpretations made were representative of the clients’ experiences.  This noted information 
obtained within the group, not provided by participants during the interviews, was bracketed 
as much as possible to ensure transparency in what information was drawn on when 
interpreting the data. 
Furthermore, the researcher’s theoretical position is also important to consider.  My 
epistemological stance is that of a critical realist which assumes that the data gathered 
provides us with an understanding of a phenomenon but that this is not a direct mirroring, 
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rather it is influenced by both the context of the participant and context of the researcher 
(Harper, 2011).  
Results 
Analysis of the data resulted in the development of three themes: Attributing 
psychological distress to HD: “you’re blaming everything on that now”; Changes across 
time: “in the past you’d just get on with it”; Therapy instils hope and fight: “a light at the 
end of the tunnel”.  
Attributing psychological distress to HD: “you’re blaming everything on that now” 
All participants appeared to attribute their psychological distress to HD; however this 
was from both a biological and psychological perspective insofar as they acknowledged the 
potential contribution of both biological and psychological factors in causing their distress.  
Most participants described, more fully, a biological understanding of psychological 
difficulties in HD.  It seemed as though people understood difficulties such as low mood, 
anxiety and irritability as being part of the disease, resulting from brain changes that occured 
due to HD: “I just assumed it’s because with Huntington’s it’s something that’s you know 
thought will happen…so it was just a case of treating the depression as a biological thing” 
(Sharon); “I think it’s definitely the biology of it [HD]” (Chris).   
In terms of understanding how people adopted this perspective it seemed that this was 
due to the discourse around psychological difficulties in the context of HD provided by the 
health care professionals seen by participants.  As Alice explained “they say they’re 
[psychological difficulties] part of the symptoms…they say that when you get to a further 
stage you’ll start to get a bit depressed”.  As such, it seemed that this biological explanation 
of psychological distress was acceptable to people with HD.  Interestingly, with regards to the 
explanations and information provided to people with HD, this seems understandable given 
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that the healthcare professionals people had contact with were often medical professionals.  
As such, participants were more frequently exposed to a medical understanding of 
psychological distress in HD.   
Furthermore, one participant explained why they held a biological understanding of 
psychological distress: “It only makes sense when I think about it as part of the Huntington’s 
biological thing” (Sharon).  It seemed that this participant could only understand her 
emotional experience from a biological perspective, as to her, nothing else in her life could be 
responsible for it.  Consequently, an explanation which removed the control from her over 
her emotions was more acceptable as it seemed that if she had control over how she felt then 
she would have already actively sought to change them.  However, while this biological 
attributional process seemed to be participants’ predominant experience there were also some 
additional views.   
In addition to a biological understanding, some participants also commented that they 
were not confident as to the cause.  There was an ambivalence which seemed to be driven by 
a feeling that health care professionals did not fully know the cause of psychological distress 
in HD.  Lyndsey’s experience was that “they often say they don’t know if depression’s linked 
to HD and that they don’t know either way”.  It seemed that while participants were often 
accepting of a biological understanding there remained some confusion and uncertainty with 
Lyndsey going on to say “I said earlier I think it’s just the HD but I don’t. I think it’s both 
[due to biological and psychological factors]”.  Therefore, it seemed that being given the 
space to reflect on their understanding and where this had originated, enabled 
acknowledgement of the potential for psychological difficulties to occur in response to living 
with HD.  However, this psychological understanding seemed to be more implicit and subtle 
resulting from a belief that a biological explanation could not solely explain psychological 
2-13 
PSYCHOLOGICAL DISTRESS IN HUNTINGTON’S DISEASE 
distress in HD.  Consequently, it appeared that participants were amenable to the two 
explanations existing in parralell.   
Many participants seemed to experience HD as an uncertain and ambiguous condition 
which indirectly influenced the interpretations people made about their behaviour: “now 
everything’s illness and it doesn’t matter. You can’t get that out of your head really” (Chris).  
Indeed, this uncertainty and ambiguity seemed to induce feelings of anxiety and/or low mood 
for many participants.  As such, many participants reported having undertaken genetic testing 
to reduce the anxiety of not knowing whether they were gene carriers: “If I didn’t have the 
test, I would feel anxious” (Sue) and “…I think I’d have been probably down and upset about 
it if I hadn’t have had the test and just sat in limbo not knowing” (Anna).  However 
confirmation of the gene seemed to result in further ambiguity with regards to living with 
HD.  This dilemma was highlighted by one participant’s experience: “it is that blessing and a 
curse to get to know that something massive is gonna happen to you that’s not necessarily 
going to be pleasant” (Sue).  Furthermore, participants explained how they could not be 
certain how and when they would be affected by the condition.  This ambiguity was often 
described to lead to feelings of anxiety and low mood.  
No one can tell you what kind of symptoms you’re going to get.  I suppose that 
makes you a bit anxious because you don’t know … And it’s like, very hard to, 
you’ll never know definitely even at the time when stuff happens, it’s like he 
[doctor] said it can be any way kind of thing, it’s not a set path which is really 
hard. (Alice)  
 While psychological distress was not attributed to the biological nature of HD, 
nonetheless, it was a result of living with HD.  Additionally, despite not knowing 
exactly what may occur for people in the future, feelings of anxiety and low mood were 
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also triggered by an understanding that the experience of physical and psychological 
difficulties was inevitable; 
You know what’s coming because you’ve seen it … you just worry about, 
obviously you know what’s going to happen so that makes you feel a bit 
depressed when you’re thinking about it and a bit anxious that you know what’s 
happening. (Alice) 
I suppose it does feel like a ticking time bomb but it’s meant to go on for quite a 
long time. (Lyndsey) 
It appeared as though both the ambiguity and inevitability of the potential difficulties 
people could experience felt daunting.  The anticipation of both physical and psychological 
difficulties seemed to induce feelings of anxiety and helplessness resulting in low mood for 
some participants.  Additionally, many participants talked about their experience of 
psychological distress, in particular anxiety, in the context of worrying about the genetic 
transmission of HD.      
You don’t really want to think about that type of thing because at the moment I’m 
quite selfish.  I just think about myself and get on with my day.  It’s almost like 
you can’t cope with thinking about if the boys had it as well…but I always worry 
about the boys getting it. (Chris) 
For those participants with children, this seemed to provide an additional cause of 
distress.  It seemed that in order to manage this cause of distress avoidance was often used 
due to an inability to control the situation.   
Indeed, all participants described their experience of HD as removing control from 
them which seemed to result in feelings of helplessness.  One participant explained “…it 
[HD] takes over at the end of the day, I can’t really do anything about it” (James).  There was 
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almost a sense of being resigned to the idea that people were in the hands of HD and had to 
accept “that lack of control in your life that, really, you’re not master of your own destiny at 
all despite what you might think” (Sue).  This sense of helplessness was further highlighted 
by Chris: “sometimes you just feel like you’re living on a sinking ship”.  It appeared that 
participants were very aware of the fact that there was currently no treatment or cure for HD 
and as such there was nothing they could do, resulting in feeling out of control.   
Changes across time: “in the past you’d just get on with it”   
Further to people’s current understanding of their psychological difficulties, it seemed 
that some participants’ experience of their difficulties had changed from prior to having the 
HD gene confirmed, reflecting a dynamic process.  Now participants attributed any instance 
of psychological distress to HD “whereas in the past you’d just get on with it” (Chris) and 
often would not pay much attention to becoming irritable or anxious.  In particular, when 
people started to experience difficulties following finding out about the HD gene, it seemed 
that they were increasingly likely to attribute them to the biological progressive nature of HD: 
“when something suddenly changes like that you think, you automatically think well the 
cause might be HD” (Simon).  Chris further explained that “you’ve got something to blame it 
on now”, describing “if you’re tired it’s because of the gene, you know, if you get annoyed 
it’s because of the gene”.  This understanding was also described by Dave who commented 
“the question is do I over analyse? If I weren’t thinking about it would my mind actually 
bother about it?  A couple of years ago I wouldn’t even have thought about it I would have 
just brushed it off”.  These comments reflect the idea that once people know they have the 
HD gene, any difficulties are viewed through this lens and are subsequently attributed to HD.  
However, prior to knowing about the gene they were likely to attribute their experience of 
psychological distress differently and in some cases, ignore it or minimise it.  
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Another specific change in attributional process for some participants regarded the 
origin of emotional responses, and whether these were part of their personality or part of the 
HD.  As James explained “I don’t know if it’s probably the early signs of Huntington’s back 
then or if it’s just part of me”.  This conflict of understanding was further suggested by Sue 
who talked about her experience of irritability and anger as “part of the condition” but went 
on to say “but I’m a defensive person so that’s part of my personality”.  Again, it appeared 
that the additional lens of HD had provoked a re-assessment as to where experiences came 
from and how they could be understood.     
Again, participants also expressed the view that their experiences could be due to an 
interplay of factors.  Dave seemed to understand his psychological distress as being part of 
his personality, however with the potential for HD to accentuate these: “I don’t think the 
HD’s brought them on, I think I’ve had them anyway…it’s just I’ve always had them and 
now they could get worse because of this”.  Lyndsey similarly recognised longstanding 
difficulties which had changed: “I’ve always been inclined to get a bit down but this is on a 
completely different level”, which seemed to suggest that her experience of psychological 
distress was enhanced in the context of HD.  These comments highlight the process of change 
in participants’ understanding of their experience.  While people previously understood their 
psychological distress to be a part of their personality, the knowledge of HD had altered their 
understanding.  As such there seemed to be an understanding that HD had increased previous 
levels of anxiety and low mood.  Furthermore, HD had not only influenced how participants 
understood their present and future psychological distress but it had also influenced how they 
viewed their past experience of psychological distress.   
  Conversely, one participant continued to see their experience of psychological distress 
prior to and following confirmation of the HD gene as separate.  On discussing experiencing 
a period of depression prior to knowing about HD, Simon commented “I don’t attribute any 
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of that to HD related stuff, that was really to do with work pressures”.  This highlights a 
situational and psychological understanding of his experience.     
 There certainly seemed to be an understanding from some participants that HD 
had the ability to accentuate some of the negative aspects of a person’s personality.  
Therefore, it seemed that while they acknowledged that some difficulties were almost 
an inherent part of their personality, they believed that the HD may heighten some of 
these personality factors.  Interestingly, there was no mention of the impact of HD on 
more positive emotional responses people experienced in their lives.  In addition, 
Simon understood personality to be a dynamic process in itself: “I mean everybody’s 
personality is different and the problem is personality is changing”.  Seemingly, Simon 
understood personality as having the potential for change.  It therefore seemed that it 
may be hard to conclude the cause of psychological distress on the basis that 
personality changes over time.  Therefore, there appeared to be an understanding that 
difficulties over time may have numerous potential causes and that while HD 
progresses over time, so can other causes such as personality.   
Therapy instils hope and fight: “a light at the end of the tunnel”   
Most participants, while not having had any psychological therapy before, described 
seeing the opportunity to engage in MBCT as positive.  Most participants were not sure what 
to expect but there seemed to be a hope that psychological therapy could support them to 
manage and control the psychological difficulties they experienced: “I think for me it feels 
that maybe there is a bit of a light at the end of the tunnel” (Lyndsey). 
It also seemed that people felt that taking part in therapy was a means of fighting 
against some of the difficulties HD could bring.  This fight was articulated by Sharon who 
commented: “I wouldn’t want to just be putting up with it if there was something I could do 
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about it”, with psychological therapy providing the possibility of being able to play a role in 
this.  Furthermore, Simon explained “dealing with anxiety is important because it’s there 
constantly…yep control of anxiety and worry is important”, again with the hope that 
psychological therapy could contribute to this. 
Six participants were on medication to help manage psychological distress.  However, 
it seemed that most participants preferred the idea of psychological therapy to medication.  
This preference seemed to originate from the idea of medication being chemicals placed into 
the body whereas psychological therapy, if helpful, could provide participants with an 
alternative or additional approach to medication that was less intrusive: “I’d rather something 
more natural than medication” (Alice).  This was further emphasised by Simon who 
commented:   
The drugs out there at the moment are probably quite crude and may suppress 
other things…So I think from my point of view anything you can, as it were, do 
naturally and do by going through a process of erm, of psychological awareness 
and you know exercises if you like and routines has to be a good thing.  
 It was apparent that, where possible and optional, people were engaging in the 
therapy with the hope that this could provide them with an alternative, or in some cases 
additional, approach to manage the psychological difficulties they currently 
experienced and potentially may experience in the future.  All participants talked about 
how they did not have any particular expectations of psychological therapy, rather the 
idea of accessing psychological therapy provided them with hope that their level of 
psychological distress, either now or in the future, could be managed or reduced.    
Despite the hope people had for psychological therapy to help them with the 
psychological difficulties they experienced, due to their biological understanding of 
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psychological difficulties in HD, there seemed to be some uncertainty as to how it might 
help.  Alice discussed how she was “not too sure” about how therapy could help “because 
apparently everyone takes the tablets so I don’t know”.  It seemed that people did not have 
much information or understanding of psychological approaches, particularly within the 
context of HD, and as such were not able to contemplate how it would be effective.  
However, despite this uncertainty, the hope for psychological therapy to be beneficial to 
participants was maintained: “even if it’s minimal the difference it makes, it still is worth 
doing” (Sue). 
There seemed to be an understanding that engaging in psychological therapy required 
a certain mind set in order for the therapy to be beneficial, potentially as a result of the 
uncertainty of how it may help.  A number of participants used the term “open-minded” as a 
characteristic they felt important when taking part.  Dave explained “I’m always willing to 
try new things” while James commented “I’m open-minded to it and see where it goes you 
know, see what happens”.  In part it seemed that this open-mindedness was required due to 
information people had received regarding the biological nature of some psychological 
difficulties:  
I’m hoping I’ve got an open mind about it…because like I said we’re all kind of, 
we’re told you know that things are a certain way and that’s you know kind of 
what we have to deal with like you know, low mood and depression etcetera. 
(Sharon) 
Seemingly, while participants were hopeful that psychological therapy could help them 
manage any psychological difficulties they experienced, there was an element of reservation 
with regards to how much it could help.  This was reflected in comments from some 
participants who expressed an understanding and expectation that psychological therapy 
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would have its limits, particularly as HD progressed: “there’s probably a limit to how far it 
will go when it starts, you know, getting progressively worse…there’s probably a limit to 
what it can do” (Chris).      
In addition to being open-minded, there also seemed to be an understanding that 
therapy would require effort on the part of the participant.  The majority of participants 
seemed committed to actively engaging with the therapy.  Sue commented “I think I’ve got to 
really make the effort” and Sharon explained “I’m going to do my best”.  These comments 
regarding therapy requiring effort, and the concept of being open-minded, potentially 
refelected the dissonance between understanding psychological distress as a consequence of 
the biological neurodegenerative process of HD and adopting a psychological approach in 
managing this.  When questioned regarding how participants thought a psychological 
approach could help considering many adopted a biological understanding, participants 
generally stuggled to provide an answer: “I haven’t a clue.  That’s what I’m I’m a little bit 
confused about, a lot confused about” (Sharon).  However, despite this, it seemed that the 
hope that it could help people to manage their distress was more important to participants.   
Discussion 
The current analysis of people with HD’s experience and understanding of 
psychological difficulties in HD and expectations of psychological therapy revealed three 
superordinate themes.  Findings suggest that their understandings of the causes of 
psychological difficulties are varied with participants describing different potential causes of 
their psychological difficulties including both biological and psychological accounts.  There 
was an acknowledgement that psychological difficulties were sometimes reactive in terms of 
being a response to living with HD.  However, there was also a more dominant understanding 
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that ran alongside a psychological account whereby psychological difficulties were attributed 
to the biological process of HD and, subsequently, were inevitable.   
Indeed, psychological difficulties in HD are likely due to a combination of 
psychological and neurobiological factors (Weintraub & Burn, 2011).  However, research has 
tended to emphasise neurobiological factors (e.g. Gregory et al., 2015; Van den Stock et al., 
2015) above the more psychological explanations (e.g. Nimmagadda et al., 2011).  These 
findings indicate that medical models are incorporated far more than psychological models in 
HD insofar as accounts to which people are exposed.  This is consistent with the research 
looking at psychological difficulties in HD which have focussed on the biological causes 
(Gregory et al., 2015; Van den Stock et al., 2015).  
Interestingly, understandings and experiences of psychological distress seemed to 
reflect a dynamic process for many participants as opposed to being static.  In their self-
regulation model of chronic illness, Leventhal, Meyer and Nernez (1980) propose that 
people, based on their experience of their illness, develop their own illness beliefs to help 
them make sense of their illness and subsequently cope with and adapt to their illness.  
Indeed it has been suggested that people’s beliefs about their illness are often influenced, 
unsurprisingly, by the information they are surrounded by and as such these beliefs are 
changing dependent on the information to which a person is exposed (Leventhal, Leventhal & 
Cameron, 2001).   
Furthermore, prior to the individual themselves finding out they have the gene, for 
many there was an awareness that HD was in the family and they were at risk.  However, 
finding out they themselves had the gene resulted in an increased level of distress and a 
different understanding regarding their experience of distress, with most psychological 
distress now being attributed to HD.  Therefore, the current research demonstrates how 
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people’s experience of psychological distress, across the progression of HD is likely to 
change and as such may require different approaches dependent on where the individual is in 
their HD journey.         
In a systematic review examining the psychological impact of predictive testing, an 
initial increase in feelings of hopelessness was found (Crozier, Robertson & Dale, 2015).  
The current research also identified the hopelessness that some participants felt as a result of 
living with HD which further seemed to impact on their mood.  Furthermore, how an 
individual perceives their chronic illness, including the sense of control, has been shown to 
contribute to both their physical and psychological well-being (Arran et al., 2013; Heijmans, 
1998; Simpson, Lekwuwa &  Crawford, 2013).  Indeed, the hopelessness some participants 
felt seemed to be associated with participants’ sense of control over their health and life in 
general.  Certainly, it was apparent in the current research that many participants felt HD had 
taken this away. 
In addition, the current findings support those of Arran et al. (2013) who found that 
people with HD felt they had little control, both personally and with regards to the treatment 
of HD.  Indeed, in the current research, the option to engage in psychological therapy, in 
particular MBCT, appeared to enable participants to feel they were regaining some of the 
control they had lost and they hoped would enable them to feel more in control in the future.  
Similarly, they felt they were being proactive in improving their well-being as opposed to 
waiting for what they felt was inevitable.  Thus increasing a person’s perception of control 
over their illness may result in improved wellbeing (Hagger & Orbell, 2003).   
However, similar to the experience of people with PD (Eccles, Murray & Simpson, 
2011), due to the progressive degenerative nature of HD, it is unlikely, and potentially 
unrealistic, that people with HD will hold positive control beliefs.  Consequently, it may be 
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more effective to work with people with HD to accept and learn to live with reduced control 
and the ambiguity HD brings.  Certainly, living with the unpredictable and uncontrollable 
nature of HD, acceptance is of particular importance (Helder et al., 2002).  In fact, individuals 
undertaking MBCT, the therapy in which the participants were due to engage have 
emphasised its value in enabling acceptance (Mason & Hargreaves, 2001).      
Further to struggling with the perception of a loss of control, the uncertainty 
associated with HD often resulted in feelings of anxiety.  Indeed, anxiety has been shown to 
be one of the most common psychosocial responses to living with a chronic illness (Livneh & 
Antonak, 2005).   Novak and Tabrizi (2010) noted that people can often find knowing they 
have the HD gene easier than the uncertainty of HD.  While this was true for the majority of 
participants, this then resulted in a different uncertainty that people had to manage i.e. the 
uncertainty regarding when the disease would begin to affect them.  The Huntington’s 
Disease Society of America note “There’s no typical person with HD.  Each individual has 
complex unique needs” (1999, p.7).  As such the unique and unpredictable nature of HD is 
likely to increase a person’s anxiety, leaving them uncertain regarding their future and the 
impact the disease may have.   
Additionally, due to the mean age of onset of around 40 years of age, gene carriers 
may have already passed the gene on to their children (Duistherof, Trijsburg, Niermjer, Roos 
& Tibben, 2001).  Subsequently, there were wider implications of having the HD gene than 
just those of the individual.  Indeed for those who talked about having children, anxieties 
were discussed as a result of the potential to have passed the gene on.  Furthermore, while 
each individual’s experience of HD is likely to be different, most people, given its genetic 
transmission will have seen a family member, most likely a parent, develop the disease and 
will be familiar with the changes this causes (Novak & Tabrizi, 2010).  Consequently, having 
seen the disease progress in a loved one and anticipating what their own disease progression 
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may be, anxiety levels may be expectedly high.  These were experiences described by many 
participants, by which it was apparent that a psychological understanding of distress was also 
accepted.    
Furthermore, with regards to people’s expectations of psychological therapy, 
participants felt it provided them with an alternative approach to medication, giving them 
hope of being able to manage and gain some control over their psychological difficulties 
believed to be associated with HD.  Indeed, a number of participants currently taking 
medication commented on the hope that they may not have to take them in the long term.  
However, an important caveat is that all participants had already signed up to engage in a 
pilot trial of MBCT and as such may have already been open to psychological approaches 
and interventions.  Consequently, there is the potential for a bias toward a psychological 
approach to have been reported as those who did not opt in to engage in the MBCT 
programme were not recruited.   
Interestingly, previous studies have shown patient outcome expectations to be 
important in engagement and completion of therapy programmes, including CBT and MBCT 
(Snippe et al., 2015).  “Outcome expectations reflect patients’ prognostic beliefs about the 
consequences of engaging in treatment” (Constantino, Arnkoff, Glass, Ametrano & Smith, 
2011, p.184).  In a sample of people with diabetes, Snippe et al. (2015) found that people 
were more likely to complete and benefit from CBT and MBCT if they had high expectations 
of the outcomes. 
In addition, context has been suggested to be a potential influence on an individual’s 
expectations insofar as if a person has prior experience of a psychological therapy then it is 
likely that their expectations of future therapy will be influenced by their previous experience 
(Constantino et al., 2011).  For example, a person who has had a positive experience of 
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therapy is more likely to have higher expectations of future therapy than someone who had a 
negative experience of therapy.  Of the participants in the current study, four had previously 
accessed therapy unrelated to HD, some of whom had a positive experience and some who 
did not find it helpful.  However, this was often accompanied by the understanding that the 
timing of the therapy influenced how helpful it was.  Indeed, despite some participants having 
a negative experience of previous therapy, this did not seem to influence their expectations of 
the MBCT course, potentially due to their hope that it would help.      
Indeed, while expectations may be important in terms of engagement, the hope that is 
created as a result of patients’ positive expectations may also influence outcomes (Frank, 
1973).  In the current study the concept of hope was discussed, in some cases explicitly and 
in others implicitly.  While participants did not seem to have many expectations of 
psychological therapy it was apparent that, to many, it offered hope of being able to manage 
their psychological distress better.   
Interestingly, despite a dominant biological understanding of distress, participants 
were interested in a psychological approach to its treatment, suggesting a certain level of 
dissonance.  The theory of cognitive dissonance (Festinger, 1957) suggests that individuals 
have a tendency to seek consistency regarding their cognitions (i.e. beliefs).  When there is 
not consistency, dissonance occurs.  Participants were engaging in psychological therapy 
despite holding a biological understanding of psychological distress.  However, it is 
suggested that there are many situations where dissonance is unavoidable (Festinger, 1962).  
Considering that there is no cure for HD and the desire of some participants to avoid 
medication where possible, this dissonance may have been compensated for with hope.  
Consequently, it may be suggested that even though dissonance can occur between a person’s 
beliefs and their actions (i.e. holding a biological understanding and accessing psychological 
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therapy), this is tolerable when the potential benefit of the dissonant action has the potential 
to outweigh this conflict.           
Study Limitations 
 However, this study has a number of limitations.  The only individuals invited to be 
participants were those who had already consented to take part in an MBCT trial.  People 
who had not signed up to the MBCT trial were therefore excluded.  Subsequently, it may be 
suggested that these individuals may be more psychologically minded and more open to 
psychological approaches than those who declined to take part in the trial.  Furthermore, the 
consideration of a psychological understanding of distress, on some occasions, seemed to be 
a result of taking part in the current research .  It seemed that having time to think about an 
alternative perspective enabled people to reflect on their experience and understanding, 
something which may not have been the case otherwise.  Therefore, it cannot be concluded 
that the understandings and experiences of psychological difficulties and expectations of 
psychological therapy, as described by participants, would reflect those of people who were 
not signed up to engage in MBCT.  Consequently, it may be of interest to investigate the 
understanding and experience of psychological distress in people who were not open to the 
idea of engaging in psychological therapy.   
 Additionally, the lead researcher took part in the MBCT trial alongside participants in 
the current study (after having interviewed them).  This took place prior to the completion of 
the data analysis.  It is therefore possible that the lead researcher developed a greater insight 
into the lives and experience of participants than would have been possible during a 60-
minute interview.  However, in order to manage this, a reflective diary was kept to maintain 
an awareness of understanding that was obtained during the MBCT course compared with 
that obtained from the interviews.     
2-27 
PSYCHOLOGICAL DISTRESS IN HUNTINGTON’S DISEASE 
Clinical implications and future research  
 The current research highlights a number of clinical implications.  Firstly, it has been 
demonstated that people with HD may be open to a psychological understanding of distress in 
HD and subsequently psychological approaches.  Indeed, the openness to considering 
psychological factors as influential in the experience of distress and acceptance of a 
psychological approach has already been demonstrated in people with another 
neurodegenerative condition, PD (Oehlberg et al., 2008).  Consequently, the provision of, and 
access to, psychological therapy services for people with HD should be considered.  Indeed, 
findings (Tabrizi et al., 2012; Eidelberg & Surmeier, 2011) support the argument for non-
pharmacologic approaches such as CBT for the management of behavioural difficulties such 
as irritability, either alongside or as an alternative to medication.  Currently, psychological 
support is not prioritised in HD, potentially due to the understanding that psychological 
distress occurs as part of the HD process.  However, here there is indication that 
psychological approaches may be acceptable to people with HD with the potential to improve 
well-being.      
 As the current research only examined the perspectives of people with pre-
symptomatic HD it would be valuable, where possible, to obtain the perspectives of people at 
different stages of the HD process.  It is possible that people with more advanced HD may 
struggle to engage with psychological therapy, particularly if there has been a significant 
impact on a person’s cognition.   
Conclusions  
Overall, the current research has demonstrated that participants accepted both a 
biological and psychological understanding of psychological distress, however with a 
biological view seeming to dominate.  Furthermore, participants’ experiences were 
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changeable over time, dependent on the context in which the individual was experiencing 
distress.  Finally, psychological therapy was accepted as an approach to support people to 
manage their distress.  This was often accompanied with the hope this could provide an 
alternative or additional approach to medication that could support people with HD to feel 
more in control over their experience.   
 
   
2-29 
PSYCHOLOGICAL DISTRESS IN HUNTINGTON’S DISEASE 
References  
Arran, N., Craufurd, D. & Simpson, J. (2013). Illness perceptions, coping styles and 
psychological distress in adults with Huntington’s disease. Psychology, Health & 
Medicine, 19, 169-179. doi: 10.1080/13548506.2013.802355.  
Aubeeluck, A., & Wilson, E. (2008). Huntington’s disease. Part 1: essential background and 
management. British Journal of Nursing, 17 (3), 146-151.   
Bury, M. (1982). Chronic illness as biographical disruption. Sociology of health and illness, 4 
(2), 167-182.  
Charidimou, A., Seamons, J., Selai, C., & Schrag, A. (2011). The role of Cognitive-
Behavioural Therapy for patients with depression in Parkinson’s disease. Parkinson’s 
disease, 2011. doi: 10.4061/2011/737523. 
Constantino, M. J., Arnkoff, D. B., Glass, C. R., Ametrano, R. M., & Smith, J. Z. (2011). 
Expectations. Journal of Clinical Psychology, 67 (2), 184–192. doi: 
10.1002/jclp.20754. 
Craufurd, D., & Snowden, J.S. (2011). Neuropsychiatry and Neuropsychology. In G.P. Bates, 
S.J. Tabrizi, & L. Jones, Huntington’s Disease (4th Edition). Oxford University Press, 
New York: NY.  
Craufurd, D., Thompson, J.C., & Snowden, J.S. (2001).  Behavioral changes in Huntington’s 
disease. Neuropsychiatry, Neuropsychology and Behavioral Neurology, 14 (4), 219-
226.   
Croizer, S., Robertson, N., & Dale, M. (2015). The psychological impact of predictive 
genetic testing for Huntington’s disease: A systematic review of the literature. Journal 
of Genetic Counselling, 24, 29-39. doi: 10.1007/s10897-014-9755-y.  
2-30 
PSYCHOLOGICAL DISTRESS IN HUNTINGTON’S DISEASE 
Dale, M., & van Duijn, E. (2015). Anxiety in Huntington’s disease. The Journal of 
Neuropsychiatry and Clinical Neurosciences, 27 (4), 262-271. doi: 
10.1176/appi.neuropsych.14100265.  
Dewhurst, K., Oliver, J., Trick, K.L.K., & McKnight, A L. (1969). Neuro-psychiatric aspects 
of Huntington’s disease. Confin Neurol, 31 (4), 258-268. doi: 10.1159/000103486. 
Dobkin, R.D., Menza, M., Allen, L.A., Gara, M.A., Mark, M.H., Tiu, J., … Friedman, J. 
(2011). Cognitive behavioural therapy for depression in Parkinson’s disease: A 
randomised, controlled trial. American Journal of Psychiatry, 168 (10), 1066-1074. 
doi: 10.1176/appi.ajp.2011.10111669.  
Duff, K., Paulsen, J. S., Beglinger, L. J., Langbehn, D. R., Stout, J. C., & Predict-HD 
Investigators of the Huntington Study Group. (2007). Psychiatric symptoms in 
Huntington’s disease before diagnosis: the predict-HD study. Biological Psychiatry, 
62 (12), 1341-1346. doi: 10.1016/j.biopsych.2006.11.034. 
Duistherof, M., Trijsburg, R.W., Niermejer, M.F.,Roos, R.A.C., & Tibben, A. (2001). 
Psychological studties in Huntington’s disease: Making up the balance. Journal of 
Medical Genetics, 38, 852-861. doi: 10.1136/jmg.38.12.852.  
Eccles, F.J., Murray, C., & Simpson, J. (2011). Perceptions of cause and control in people 
with Parkinson’s disease. Disability and Rehabilitation, 33, 1409-1420. 
Eidelberg, D., & Surmeier, D. J. (2011). Brain networks in Huntington disease. The Journal 
of clinical investigation, 121 (2), 484-492. doi: 10.1172/JCI45646. 
Festinger, L. (1957). A theory of cognitive dissonance. Stanford University Press. 
Festinger, L. (1962). A theory of cognitive dissonance. (Vol. 2). Stanford University Press. 
Fitzpatrick, L., Simpson, J. & Smith, A. (2010). A qualitative analysis of mindfulness-based 
cognitive therapy (MBCT) in Parkinson's disease. Psychology and Psychotherapy: 
Theory, Research and Practice, 83 (2), 179-192. doi: 10.1348/147608309X471514.  
2-31 
PSYCHOLOGICAL DISTRESS IN HUNTINGTON’S DISEASE 
Frank, J. D. (1973). Persuasion and healing (2nd ed.). Baltimore: Johns Hopkins University 
Press. 
Gregory, S., Scahill, R.I., Seunarine, K.K., Stopford, C., Zhang, H., Zhang, J., … & Track-
HD Investigators. (2015). Neuropsychiatry and white matter microstructure in 
Huntington’s disease. Journal of Huntington’s Disease, 4, 239-249. doi: 
10.3233/JHD-150160. 
Gu, J., Strauss, C., Bond., R., & Cavanagh,K. (2015). How do mindfulness-based cognitive 
therapy and mindfulness-based stress reduction improve mental health and well-
being? A systematic review and meta-analysis of mediation studies. Clinical 
Psychology Review, 37, 1-12. doi: 10.1016/j.cpr.2015.01.006.  
Hagger, M.S., & Orbell, S. (2003). A meta-analytic review of the common-sense of illness 
representations. Psychology and Health, 18 (2), 141-184. doi: 
10.1080/088704403100081321.  
Harper, D. (2011). Choosing a qualitative research method. In D. Harper & A.R. Thompson 
(Eds.) Qualitative research methods in mental health and psychotherapy: A guide for 
students and practitioners. John Wiley & Sons Ltd, p.83-98.  
Heijmans, M. (1998). Coping and adaptive outcome in chronic fatigue syndrome: Importance 
of illness cognitions. Journal of Psychosomatic Research, 45, 39-51.  
Helder, D.I., Kaptein, A.A., van Kempen, G.M.J., Weinman, J., van Houwelingen., H.C., & 
Roos, R.A.C. (2002). Living with Huntington’s disease: Illness perceptions, coping 
mechanisms, and patients’ well-being. British Journal of Health Psychology, 7 (4), 
449-462. doi: 10.1348/135910702320645417.  
Ho, A.K., Gilbert, A.S., Mason, S.L., Goodman, A.O., & Barker, R.A. (2009). Health related 
quality of life in HD: Which factors matter most? Movement Disorders, 24 (4), 574-
578. doi: 10.1002/mds.22412.    
2-32 
PSYCHOLOGICAL DISTRESS IN HUNTINGTON’S DISEASE 
 
Hoffman, N. (1999). Understanding the neuropsychiatric symptoms of Huntington’s disease. 
The Journal of Neuroscience Nursing, 31 (5), 309-313.  
Huntington’s Disease Society of America. (1999). A Caregiver’s Handbook for Advanced 
Stage Huntington’s disease. Huntington’s Disease Society of America, New York.  
Julien, C.L., Thompson, J.C., Wild, S., Yardumian, P., Snowden, J.S., Turner, G. & 
Craufurd, D. (2007). Psychiatric disorders in preclinical Huntington’s disease. 
Journal of Neurology, Neurosurgery and Psychiatry, 78, 939-943. doi: 
10.1136/jnnp/2006.103309.  
Kaptein, A. A., Helder, D. I., Scharloo, M., Van Kempen, G. M. J., Weinman, J., Van 
Houwelingen, H. J. C. & Roos, R. a. C. (2006). Illness perceptions and coping explain 
well-being in patients with Huntington's disease. Psychology & Health, 21 (4), 431-
446. doi: 10.1080/14768320500456947.  
Kay, C., Fisher, E. & Hayden, M. R. (2014). Epidemiology. In Bates, G., Tabrizi, S. J. & 
Jones, L. (eds.) Huntington's disease. 4th ed. Oxford: Oxford University Press. 
Keenan, K.F., Simpson, S.A., Miedzybrodzka, Z., Alexander, D.A., & Semper, J. (2013). 
How do partners frind out about the risk of Huntington’s disease in couple 
relationships. Journal of Genetic Counselling, 22, 336-344. doi: 10.1007/s10897-012-
9562-2. 
Kingma, E.M., van Duijn, E., Tinman, R., van der Mast, R.C., Raymund, A.C., & Ross, M.D. 
(2008). Behavioural problems in Huntington’s disease using the Problem Behaviours 
Assessment. General Hospital Psychiatry, 30, 155-161. doi: 
10.1016/j.genhosppsych.2007.11.005. 
2-33 
PSYCHOLOGICAL DISTRESS IN HUNTINGTON’S DISEASE 
Kirkwood, S.C., Su, J.L., Conneally, M., & Foroud, T. (2001). Progression of symptoms in 
the early and middle stages of Huntinton’s disease. Archives or Neurology, 58 (2), 
273-278. doi: 10.1001/archneur.58.2.273. 
Kloppel, S., Stonnington, C.M., Petrovic, P., Mobbs, D., Tuscher, O., Craufurd, D., … 
Frackowiak, R.S.J. (2010). Irritability in pre-clinical Huntington’s disease. 
Neuropsychologia, 48, 549-557. doi: 10.1016/j.neuropsychologia.2009.10.016.  
Kowalski, P.C., Belcher, D.C., Keltner, N.O., Dowben, J.S. (2015). Biological Perspectives: 
Huntington’s disease. Perspectives in psychiatric care, 51 (3), 157-161. doi: 
10.1111/ppc.12121.  
Kremer, B. (2002). Clinical neurology in Huntington's disease. In: Bates, G., Harper, P. & 
Jones, L. (eds.) Huntington's disease. 3rd ed. Oxford: Oxford University Press. 
Leventhal, H., Leventhal, E., & Cameron, L. (2001). Representations, procedures, and affect 
in illness self-regulation: A perceptual-cognitive model. In Baum, A., Revenson, T., 
Singer, J. (eds). Handbook of health psychology. Hillsdale, NJ: Lawrence Erlbaum 
Associates (p.19–47). 
Leventhal, H., Meyer, D., & Nerenz, D. (1980). The common sense representation of illness 
danger. Contributions to medical psychology, 2, 7-30. 
Livneh, H. & Antonak, R.F. (2005). Psychosocial adaptation to chronic illness and disability: 
A primer for counsellors. Journal of counselling and development, 83 (1), 12-20. doi: 
10.1002/j.1556-6678.2005.tb00575.x.  
Mason, O. & Hargreaves, I. (2001), A qualitative study of mindfulness-based cognitive 
therapy for depression. British Journal of Medical Psychology, 74, 197–212. 
doi: 10.1348/000711201160911. 
2-34 
PSYCHOLOGICAL DISTRESS IN HUNTINGTON’S DISEASE 
Meiser, B., & Dunn, S. (2000).  Psychological impact of genetic testing for Huntington’s 
disease: An update of the literature. Journal of Neurology, Neurosurgery and 
Psychiatry, 69 (5), 574-578. doi: 10.1136/jnnp.69.5.574.   
Nimmagadda, S.R., Agrawal, N., Worrall-Davies, A., Markova, I., & Rickards, H. (2011). 
Determinants of irritability in Huntington’s disease. Acta Neuropsychiatrica, 23, 309-
314. doi: 10.1111/j.1601-5215.2011.005653.x. 
Novak, M.J.U., & Tabrizi, S.J. (2010).  Huntington’s disease.  BMJ, 340, 34-40. doi: 
10.1136/bmj.c3109.   
Oehlberg, K., Barg, E K., Brown, G. K., Taraborelli, D., Stern, M. B., & Weintraub, D. 
(2008). Attitudes regarding the etiology and treatment of depression in Parkinson's 
disease: A qualitative study. Journal of Geriatric Psychiatry and Neurology, 21, 123-
132. doi: 10.1348/147608309X471514.  
Paulsen, J.S., Nehl, C., Hoth, K.F., Kanz, J.E., Benjamin, M., Conybeare, R., … & Turner, B. 
(2005). Depression and stages of Huntington’s disease. Journal of Neuropsychiatry 
and Clinical Neurosciences, 17 (4), 496-502. doi: 10.1176/jnp.17.4.496.  
Pla, P., Orvoen, S., Saudou, F., David, D.J., & Humbert, S. (2014). Mood disorders in 
Huntington’s disease: From behavior to cellular and molecular mechanisms. Frontiers 
in Behavioral Neuroscience, 8 (135), 1-15. doi: 10.3389/fnbeh.2014.00135.  
Segal, Z.V., Williams, J.M., & Teasdale, J. (2002). Mindfulness-based conitive therapy for 
depression: A new approach to preventing relapse. London, UK: Guildford Press. 
Simpson, J., Lekwuwa, G., & Crawford, T. (2013). Illness beliefs and psychological outcome 
in people with Parkinson’s disease. Chronic Illness, 9 (2), 165-176. doi: 
10.1177/1742395313478219. 
2-35 
PSYCHOLOGICAL DISTRESS IN HUNTINGTON’S DISEASE 
Smith, J.A., Flowers, P. & Larkin, M. (2009). Interpretative phenomenological analysis: 
theory method and research: understanding method and application. London, Sage. 
Smith, J.A., & Osborn, M. (2003). Interpretative Phenomenological Analysis. In J.A. Smith 
(Ed.), Qualitative Psychology. London: Sage.  
Snippe, E., Schroevers, M.J., Tovote, K.A., Sanderman, A., Emmelkamp, P.M.G., & Fleer, J. 
(2015). Patients’ outcome expectations matter in psychological interventions for 
patients with diabetes and comorbid depressive symptoms. Cognitive Therapy 
Research, 39, 307-317. doi: 10.1007/s10608-014-9667-z.  
Tabrizi, S. J., Reilmann, R., Roos, R. A., Durr, A., Leavitt, B., Owen, G., ... & Kennard, C. 
(2012). Potential endpoints for clinical trials in premanifest and early Huntington's 
disease in the TRACK-HD study: Analysis of 24 month observational data. The 
Lancet Neurology, 11(1), 42-53. doi: 10.1016/S1474-4422(11)70263-0. 
Van den Stock, J., De Winter, F-L., Ahmad, R., Sunaert, S., Van Laere, K., Vandenberghe, 
W., & Vandenbulcke, M. (2015). Functional brain changes underlying irritability in 
premanifest Huntington’s disease. Human Brain Mapping, 36, 2681-2690. doi: 
10.1002/hbm.22799.   
  Van Duijn, E., Kingma, E.M., & van der Mast, R.C. (2007). Psychopathology in verified 
Huntington’s disease gene carriers. Journal of Neuropsychiatry and Clinical 
Neuroscience, 19 (4), 441-448. doi: 10.1176/appi.neuropsych.19.4.441. 
Weintraub, D., & Burn, D. J. (2011). Parkinson's disease: The quintessential neuropsychiatric 
disorder. Movement Disorders, 26 (6), 1022-1031. doi: 10.1002/mds.23664. 
Yardley, L. (2000). Dilemmas in qualitative health research. Psychology and Health, 15 (2), 
215-228. doi: 10.1080/08870440008400302.   
2-36 
Running head: PSYCHOLOGICAL DISTRESS IN HUNTINGTON’S DISEASE 
 
Appendix 2-A: Background and methods of the Mindfulness-based cognitive therapy 
trial 
There has been little development regarding psychological interventions for people 
with Huntington’s disease (HD).  However, they are being developed for people with 
different neurological conditions such as Parkinson’s disease (PD; Dobkin et al., 2011).  
Mindfulness-based cognitive therapy (MBCT) has previously been piloted for people with 
PD who reported an improvement in psychological wellbeing (Fitzpatrick et al., 2010).  
Consequently, a pilot trial of MBCT is being run for people with HD to see whether it would 
be an acceptable and useful approach for people with HD. 
Additionally, due to the psychological and emotional consequences of HD, it also 
affects the people with whom they live (Aubeeluck et al., 2012).  For example, caregiver 
depression has been shown to be associated with depression in the person with HD 
(Banaszkiewicz et al., 2012).  Therefore the study will also obtain the views of a family 
member of the person with HD. 
Both qualitative (semi-structured interviews) and quantitative (e.g. Hospital Anxiety 
and Depression Scale and the Five Facet Mindfulness Questionnaire) data were collected 
from both the person with HD and their family member.  Data were collected both pre and 
post intervention.   
To be included in the study participants had had the genetic test confirming the CAG 
expansion on the huntingtin gene and were all pre-symptomatic.  All participants had clinical 
signs of low mood or depression identified in their notes or information recorded at their last 
clinic visit.  Participants were aged 18 years or over and had not had changes in their 
medication six weeks prior to the start of the MBCT intervention.  Participants were excluded 
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if they currently had suicidal intent.  Once the person with HD had been recruited they were 
asked if they have a family member or close friend who wished to participate.
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Appendix 2-B 
Table 1: Extract from Sharon’s transcript with initial summary notes and emerging themes  
Initial Notations Extract Emerging Themes  
 
 
Don’t know how therapy can 
help 
Need to be open minded 





Confusion about how therapy 
can help 
Trying to be open-minded 
A bit of help is better than 
nothing - hope 
 
 
Not going to pressure self but 
will need to try – effort 
 
Previous experience of research 
has had positive results 
P: Well since erm, well obviously, well (nurse) was saying about this course, I 
mean I didn’t realise completely what it was you know, and then the little bit of 
reading I’ve done since and everything and I’m thinking okay, but I honestly 
don’t know I’m just going to keep an open mind about it but im hopeful that 
just, you know, that I’ll be feeling a little bit better, will make me you know 
more confident to go out and do things then that’s good.  
I: So given that erm, kind of your main understanding of its psychological 
aspects such as mood and anxiety are cause by the Huntington’s how do you 
think, so for example say it’s got a biological cause, how do you think a 
psychological therapy can… 
P: I haven’t a clue, that’s what I’m a little bit confused about, a lot confused 
about, but that why I’m trying to keep an open mind about the course and you 
know, and it might help research in the future so I don’t know if it will but if it 
clears my mind then it will never work but it might just a bit and that’s better 
than nothing when you don’t have a lot of hope or anything when it gets to this 
point, so I don’t know.  Those are the questions I’ve been asking myself, they 
really are so that’s why I’m quite looking forward to when it starts. I’m not 
going to put like, huge you know, pressure on it, on myself as well but I’m 
going to do my best.  You know, and I think as well because I’ve been taking 
part in some research and there have been some results form that as well now 
and I’m thinking right okay maybe, there may be with this as well, this research 












Active role in therapy 
Hope 
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Submission 
The main emphasis of Health Psychology® is on original research in health psychology. Analytical reviews of 
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Office, please take the following steps to facilitate communication with our editorial office: 
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including the cover page, abstract, text, references, tables and figures. 
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for additional length (e.g., the paper reports on two or more studies or has an unusual or complex methodology). 
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page limit. 
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Brief reports are encouraged for innovative work that may be premature for publication as a full research report 
because of small sample size, novel methodologies, etc. Brief reports should be designated as such and should 
not exceed a total of 12 pages, inclusive of all parts of the manuscript, including the cover page, abstract, text, 
references, tables and figures. 
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mission to assure that the submission fits with the types of papers published in Health Psychology. 
The full mailing address, telephone, fax, and email address for the corresponding author should be included in 
the cover letter and title page, along with the names and affiliations of all co-authors. 
The cover letter must confirm that the manuscript has not been published, is not currently submitted elsewhere, 
and that it does not contain data that is currently submitted or published elsewhere. 
When a manuscript contains data that is part of a larger study, authors should describe the larger study and 
provide references for other study papers. Authors must be prepared to provide copies of related manuscripts 
when requested as part of the editorial review process. Authors should clarify the relationship between their 
paper, including detailed specification of the overlap in participants, measures, and analysis, and others from the 
study. The value-added scientific contribution of their study must be clearly stated in the cover letter. 
Authors of brief reports should indicate in the cover letter that the full report is not under consideration for 
publication elsewhere and similarly address potential overlap with other papers. 
Manuscripts 
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The manuscript title should be accurate, fully explanatory, and no longer than 12 words. The title should reflect 
the content and population studied. If the paper reports a randomized clinical trial, this should be indicated in the 
title. The title of brief reports should start with the words "Brief Report". 
The title page should include the names of all authors and their affiliations at the time the research was done. 
This information will be masked to ensure a blind peer review process by the editorial office. Authors should 
make sure that all other identifying information in the text of the paper is masked/removed prior to submission. 
All manuscripts must include a structured abstract containing a maximum of 250 words with the following 
sections: 
• Objective (brief statement of the purpose of the study); 
• Methods (summary of the participants, design, measures, procedure); 
• Results (primary findings); and 
• Conclusions (specific statement of the implications of the data). 
Please supply up to five keywords or brief phrases after the abstract. The Introduction should not exceed 3–4 
pages in length. The paper should be referenced appropriately but excessive citations should be avoided. 
All research involving human participants must describe oversight of the research process by the relevant 
Institutional Review Boards and should describe consent and assent procedures briefly in the Methods section. 
All statistical tests should include effect size whenever possible. 
First person language ("I", "we") should be avoided. Terminology should be sensitive to the individual who has a 
disease or disability. The journal endorses the concept of "people first, not their disability." Terminology should 
reflect the "person with a disability" (e.g., children with diabetes, persons with HIV infection, families of people 
with cancer) rather than the condition as an adjective (e.g., diabetic children, HIV patients, cancer families). 
Nonsexist language should be used. 
It is important to highlight the significance and novel contribution of the work. The translation of research into 
practice must be evidenced in all manuscripts. Authors should incorporate a meaningful discussion of the clinical 
and/or policy implications of their work throughout the manuscript, rather than simply providing a separate section 
for this material. 
Health Psychology publishes a broad array of types of papers. Authors of qualitative and measure development 
papers should read the guidelines for these types of papers, noted below. 
Qualitative Research 
Research papers that utilize qualitative methods should follow the general instructions to authors for style and 
format. We ask that authors of qualitative papers review the additional guidance below to assure that papers 
meet the following criteria utilized by Health Psychology. 
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a stand-alone study or if it fits into a larger study. For example, qualitative manuscripts may inform the 
development of a survey, use small-incident samples, or establish feasibility. The specific qualitative paradigm 
should be specified (e.g., grounded theory, qualitative descriptive approach, interpretive phenomenology) with a 
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Finally, all instrument development papers should convey how the literature base will be strengthened with the 
addition of the particular instrument along with a clear and convincing case for the clinical relevance of the 
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Critical Appraisal 
Reflections on: Understandings of psychological difficulties in people with Huntington’s 
disease and their expectations of psychological therapy’ 
 This paper will provide a summary of the research findings and the study’s strengths 
and limitations.  It will also provide a reflective account of some of the process issues 
encountered throughout the research process, including the lead researcher attending the 
mindfulness-based cognitive therapy (MBCT) group and the impact of this on data analysis.  
It will also explore the current lack of psychological services for people with HD, reflecting 
on potential reasons for this and how it may be overcome in future. 
Research overview 
The empirical paper was a qualitative exploration of people with HD’s understanding 
of psychological distress and expectations of psychological therapy.  Participants were all 
people with HD and were recruited from an existing therapy trial.  Semi-structured interviews 
were used to understand participants’ experiences and analysed using interpretative 
phenomenological analysis (IPA) following the steps described by Smith and Osborn (2003).  
Summary of research findings  
 The investigation of people with HD’s understanding of psychological distress and 
expectations of psychological therapy resulted in the development of three superordinate 
themes: (1) Attributing psychological distress to HD: “you’re blaming everything on that 
now”; (2) Changes across time: “in the past you’d just get on with it”; (3) Therapy instils 
hope and fight: “a light at the end of the tunnel”.   
The first theme reflected the understanding that HD was the cause of psychological 
distress, from both and biological and psychological perspective.  Indeed, a biological 
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understanding appeared to be the dominant understanding people held.  This seemed to come 
from information they were given by healthcare professionals that psychological difficulties 
are part of the progression of the disease.  Additionally, there seemed to be some 
ambivalence as to the cause which appeared to result in a more implicit psychological 
understanding of distress.  Similarly, the ambiguity and uncertainty associated with HD also 
seemed to be a contributing factor to participants’ psychological distress.  Consequently, 
whichever perspective participants held, and in some cases both perspectives were held 
simultaneously, the underlying cause was HD.   
In addition to how participants attributed their psychological distress, the second 
theme reflected how this attribution appeared to reflect a dynamic process.  This varied at 
different time points for example, prior to finding out about the HD gene, following receiving 
confirmation of the HD gene, and living with the anticipation of disease onset.  Furthermore, 
not only did it change over time but the knowledge of having the HD gene influenced how 
participants perceived their previous experience.  As such, participants’ beliefs about their 
psychological distress altered from how they had previously viewed it, thus influencing 
perception from the past, present and future. 
Finally, the third theme reflected the understanding that psychological therapy had the 
potential to give people with HD some control over their psychological experience.  Indeed, it 
seemed to instil hope into participants and provide a sense that, while they could not control 
the motor aspects of the disease, they could fight against the psychological difficulties they 
experienced.  Therefore, it enabled them to take an active role rather than remain passive, 
waiting for difficulties to occur.  A number of participants described currently taking 
medication to manage the difficulties they experienced, however the option of a more natural 
approach appealed to many.  However, alongside this hope was the understanding that 
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psychological therapy would require a certain mind-set and conscious effort on the part of the 
participant.   
Strengths and Limitations 
A strength of the current research is that this is the first study, to my knowledge, to 
interview people with HD about their understanding of psychological distress and 
expectations of psychological therapy.  It has therefore provided insight into the lived 
experience of people with HD, not previously sought.     
There are, however, a number of limitations to the current study.  The participants 
who took part had agreed to take part in an MBCT programme and were therefore potentially 
more open-minded to psychological approaches.  This may not have had an impact on their 
understanding of psychological distress, but it may be that their willingness to engage in 
MBCT is reflective of their perspective of psychological approaches.  Indeed, despite most 
participants having limited expectations of the course, no one commented that they thought it 
would be a waste of time.  Furthermore, after I had collected the data, I took part in the 
MBCT group and therefore had more contact with participants than would have occurred 
otherwise and as such gained more insight into participants’ experiences of psychological 
distress.  Therefore, there was a potential for this to have influenced the data analysis process.      
Reflections on the interview process 
 Considering the research topic, investigating psychological distress and psychological 
therapy, it seems important to consider my potential influence on the interviews from the 
perspective of a trainee clinical psychologist.  When conducting research interviews there is 
the potential for the researcher to influence participants’ responses as a result of the 
interaction process and potential factors such as social desirability (Hewitt, 2007).  
Consequently, coming from the position of a trainee clinical psychologist, and participants’ 
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awareness of this, I felt it was important to remain aware of my understanding of 
psychological distress and the beliefs I hold about the benefits of psychological therapy in 
order to ensure these were not explicitly revealed during the interviews.  I felt there could be 
a risk that coming from a psychological perspective would influence participants to want to 
talk about psychological distress and therapy from both a psychological and positive 
perspective.  Consequently, I tried to ensure my follow-up questions and responses remained 
neutral and did not lead participants’ responses.  On reflection, I feel that participants 
described their experience that was true to them, particularly considering people described a 
biological understanding.      
 Furthermore, I found it difficult listening to participants’ experiences of psychological 
distress, particularly hearing them describe the limited psychological support they had.  
Furthermore, I think this experience was made more difficult as a result of my attendance at 
the MBCT group.  By having more contact with participants and getting to know more about 
them and their families, I felt a great sense of empathy for the situation they were in.  I also 
felt inspired by the strength and resilience everyone showed in the face of HD and what this 
meant for their future.  Additionally, this felt particularly difficult considering I was in the 
role of researcher, rather than a trainee clinical psychologist, which requires a different 
approach and the use of different skills.  In my role as a trainee clinical psychologist I aim to 
understand a person’s experience and work collaboratively to effect change.  However, in the 
role as a researcher the aim is to obtain and understand a person’s experience (Drury, Francis 
& Chapman, 2007) without working towards changing their experience.   
Conversely, Wilde (1992) suggests that therapeutic skills can enhance the research 
process and in fact these skills cannot be completely put aside.  Therefore, I felt able to use 
my clinical skills, such as active listening and empathy, to ensure participants felt heard and 
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understood while ensuring my own beliefs were not expressed.  I feel this enabled 
participants to feel comfortable talking about their experience. 
Considering the researcher’s influence on data analysis       
 Prior to conducting the research I did not have any prior experience of HD from either 
a research or clinical perspective.  I had some previous research and clinical experience of 
working with another neurodegenerative disease, Parkinson’s disease (PD).  However due to 
the life-limiting nature of HD this seemed very different.   
After interviewing participants for the current research, as briefly discussed in the 
research paper, I attended the eight-week MBCT course in which participants had agreed to 
take part.  Eight out of the nine participants completed the course, which meant I had contact 
with most participants following the research interviews prior to completing the data analysis.  
As a result of attending the MBCT group, I felt I gained further insight into participants’ 
experience of psychological distress due to the discussions within the group.  Indeed, this was 
more than would have been gained had I only interviewed the participants and not had any 
further contact.  As such I was able to understand people’s experience of psychological 
distress within the wider context of their life experience, which felt like quite a privileged 
position to be in.  In addition, I also felt like this contributed to ensuring the quality of the 
research (Yardley, 2000) insofar as I felt I had an increased awareness of the context in which 
the clients experienced psychological distress.   
Furthermore, when I was analysing the data I was aware of my knowledge of 
psychological distress and therapy from a more general perspective as a trainee clinical 
psychologist.  As such, I was interpreting the data within both the clients’ context and my 
own professional context.  Indeed what I did notice was that my knowledge, from a 
professional perspective, was notably different from that gathered from participants.  While I 
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believe psychological therapy has the potential to improve people’s well-being I am aware 
that this comes from experience of working psychologically and a knowledge of the evidence 
base in other neurodegenerative diseases.  For example, MBCT has previously been piloted 
with people with Parkinson’s disease who found it improved their psychological well-being 
(Fitzpatrick, Simpson & Smith, 2010).  However, it felt important to continually reflect on 
how my understanding and knowledge was coming from a different place to that of the 
participants.  Indeed, they were coming from a position of lived experience which was the 
focus of the research.      
Consequently, in order to ensure my interpretations were reflective of the data, and 
not these wider understandings, I aimed as much as possible to bracket off this extra 
information.  Bracketing is a methodological device used in phenomenological inquiry which 
requires the researcher to deliberately put aside their beliefs and knowledge about the 
phenomenon under investigation (Carpenter, 2007).  This is also to continue throughout the 
research process.  In order to achieve this process I kept a reflective diary whereby I could 
record and make reflections on the insight I gained from the group that could potentially 
influence my interpretation of the data.  This reflexivity helped to identify potential 
influences that may have later affected the data analysis and subsequently enabled me to 
reduce them (Ahern, 1999).             
 Certainly, during the process of data analysis, I continued to reflect on the 
interpretations I was making, questioning whether the interpretations being made were based 
on the data collected or whether the wider knowledge I had gained during the MBCT course 
was influencing this.  I was aware that the additional contact I had with participants could 
have altered the perspective taken during the data analysis period.  For example, as the 
MBCT course progressed participants talked about finding the course helpful, describing how 
the how the mindfulness home practice was helping them.  As such it felt important to record 
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these comments and what I had taken from them as the data gathered during my interviews 
regarding participants’ expectations of psychological therapy did not reflect this.  Below is an 
extract from my reflective diary demonstrating this: 
During today’s session, Lyndsey (pseudonym) talked about how she felt better 
than she had in a long time.  She talked about how she was finding the 
mindfulness exercises particularly helpful when she is really struggling with her 
mood.  She was really positive about the MBCT course and commented on how 
she found being in a therapy group with others with HD was comforting.  She had 
been to group therapy before but due to the wide range of reasons for people’s 
attendance did not find the group helpful.  This suggests to me that therapy 
groups, specifically for people with HD, would be of benefit to people.  
(Reflective Diary)  
Therefore, I did not want to interpret participants’ expectations of psychological 
therapy in a positive light that did not exist.  While people were starting to describe the 
positive impact they felt it was having, during the interviews participants’ understandings of 
psychological therapy were that it provided them with hope but that there were no 
expectations of whether it would be helpful or not.  Consequently, to ensure transparency, a 
principle in ensuring quality in qualitative research (Yardley, 2000), when writing up the 
results I presented original quotes from participants transcripts in order to make sure my 
interpretations were indeed representative of the participants’ experiences.   
 In addition, I used supervision to ensure that the interpretations I had made from the 
data reflected the participants’ direct quotes.  One of my supervisors also took part in the 
MBCT course, therefore it was of particular importance to gain supervision from my second 
supervisor who did not know the participants and had not had any contact with them 
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throughout the research process.  This ensured that there was a perspective that could not 
have been influenced by anything other than the data from the research interviews.     
Impact of time on recruitment     
 Indeed, the potential influence attending the group had could have been avoided if I 
had analysed the data prior to the MBCT course commencing.  However, with the current 
research, timing was problematic.  The time between obtaining ethical approval and the 
commencement of the MBCT course was approximately four weeks.  During this time I had 
to recruit participants and complete all nine interviews.  Consequently, I did not have time to 
transcribe and analyse the data prior to the MBCT course commencing.   
Furthermore, there was a wider impact of this time limit in that it also restricted the 
sample of participants I was able to include in the research.  I had initially hoped that partners 
of those engaging in the MBCT course could be interviewed as well to gain insight into their 
understanding of their partners’ psychological distress and expectations of psychological 
therapy.  It has been demonstrated that people engaged in MBCT have reported an increase in 
perspective taking and empathy which has subsequently allowed them to interact more 
mindfully in relationships (Bihari & Mullan, 2014).  As such, partners of those with HD may 
be indirectly affected by their partner taking part in MBCT.  I was therefore interested in their 
perception of their partner engaging in psychological therapy and whether they expected any 
change as a result of this.  It would also have been interesting to be able to see whether 
people with HD and their partners had similar understandings or whether these diverged.     
However, due to the time limit I was unable to recruit enough partners to interview 
them in time.  Indeed, only one partner consented to take part in the research within the time 
frame I had to complete data collection.  I had planned to use IPA (Smith & Osborn, 2003) 
whereby I would analyse the data of people with HD and their partners separately as two 
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distinct groups.  As such, it did not seem ethical to interview one participant with the 
potential for their data to be excluded from the research.  Therefore, I explained to the partner 
who had consented to take part my reasons for not interviewing them and including them in 
the research.  Consequently, the priority of the research became to interview people with HD 
to obtain insight into their experience.   
In addition, with regards to future research, it may be important to interview partners 
to obtain their perspective on psychological distress in HD given the impact it has been 
shown to have on both the physical and psychological well-being of those around the person 
with HD (e.g., Aubeeluck, Buchanan & Stupple, 2012; Williams et al., 2009).  
Absence of psychological services for people with HD 
 Interestingly, what became apparent during the interviews, although was not specific 
to the focus of the present research, was the lack of psychological support available to people 
with HD.  Indeed, if any support were available, this was unknown to the participants.  I 
found it frustrating to learn of the lack of specialist psychological input for people with HD, 
particularly as the importance of a multi-disciplinary approach in the management of HD and 
its associated difficulties has been argued (Veenhuizen & Tibben, 2009).  Furthermore, it 
seemed that people were experiencing levels of distress that could be supported by a 
therapeutic approach.  Indeed, many participants talked about not having anyone to share 
their worries with as they did not want to burden their partners and families.  As such they 
were attempting to cope on their own, with their main contact with health care professionals 
being at the HD clinic when they attended for review.       
 I wondered whether the absence of psychological input for people with HD may be, in 
part, reflective of the dominant biological understanding of psychological distress in HD.  
Indeed, if people’s beliefs regarding their illness are influenced by the information they have 
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around them (Leventhal, Leventhal & Cameron, 2001) then it seems understandable that 
people would hold a biological understanding of psychological distress.  Consequently, the 
dominant biological perspective taken would also suggest medication would be the assumed 
treatment option for people with HD.  Indeed, participants spoke about assuming medication 
was the only option given the biological nature of their distress.  As such, if psychological 
distress is to be understood from an alternative perspective, then the way in which it is talked 
about should be addressed.   
On discussing a psychological approach during the research, participants spoke of 
their hope that it could improve their psychological well-being.  Indeed, this seemed to be in 
relation to regaining some control over their psychological experience related to HD.  
However, on reflection, while participants may be able to develop a sense of control, 
considering the uncontrollable nature of HD, acceptance may also be important for people 
with HD.  Consequently, approaches such as acceptance and commitment therapy (ACT) 
may support people to manage their psychological distress.  Indeed ACT aims to increase a 
person’s psychological flexibility focusing on mindfulness, acceptance and behaviour change 
in line with a person’s values (Hayes, Luoma, Bond, Masuda, & Lillis, 2006).  Considering 
the unchangeable and degenerative nature of HD being able to embrace one’s experience 
without trying to change it, instead accept it, seems important.   
Impact on self of attending the MBCT course 
Additionally, I felt very grateful to have been able to take part in the MBCT course.  This 
was an experience that is not afforded to many trainee clinical psychologists and I feel this 
benefitted me from a personal, professional and research perspective.  Indeed, I felt I was 
able to engage with this from both the perspective of a participant and an observer.  On the 
one hand I took part in each session, contributed to group discussion and engaged with the 
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home practice exercises.  From another perspective, being able to observe a qualified clinical 
psychologist with a wealth of experience in MBCT felt invaluable.  I feel I have learned a lot 
about how MBCT is delivered and what it entails, how to manage group dynamics and the 
benefits of your own investment in a model.  Additionally, since completing the group I have 
continued with the mindfulness practice at home and maintained the ethos of the model.  I 
believe this has enabled me to manage the demands and stress occurring throughout my thesis 
journey and training more generally.  I have used some of the exercises at times of high stress 
and others as a means of personal care.  I believe this is something I will continue to benefit 
from throughout my qualified career.   
Conclusions 
This critical appraisal has been used to reflect on some of the important issues that 
arose during the research.  I have reflected on the interview process and how my role as a 
trainee clinical psychologist may have influenced this as well as the impact hearing people’s 
stories had on me.  I further explored some of the issues that arose around the data analysis 
process, discussing the potential impact of myself attending the group.  Furthermore I 
explored how time acted as a barrier to my original research proposal resulting in only being 
able to interview people with HD.  However, although having to interview participants within 
a short space of time resulted in partners being unable to participate I believe this enabled a 
thorough and detailed understanding of the experiences of people with HD.  Finally, I 
reflected on the lack of psychological services for people with HD, concluding with some 
reflections around the impact attending the group had on me both personally and 
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18 September 2015 
 
Miss Rachael Theed  





Dear Miss Theed 
 
Study title: Understandings of psychological difficulties in Huntington’s 
disease and expectations of psychological therapy 
REC reference: 15/YH/0377 
IRAS project ID: 184010 
 
Thank you for your letter of 14 September 2015, responding to the Committee’s request for 
further information on the above research and submitting revised documentation. 
 
The further information has been considered on behalf of the Committee by the Chair. 
 
We plan to publish your research summary wording for the above study on the HRA website, 
together with your contact details. Publication will be no earlier than three months from the 
date of this opinion letter.  Should you wish to provide a substitute contact point, require 
further information, or wish to make a request to postpone publication, please contact the 




Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a Favourable ethical opinion for the 
above research on the basis described in the application form, protocol and supporting 
documentation as revised, subject to the conditions specified below. 
 
Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the start of the 
study. 
 
The Chair noted that if recruitment is expanded and an additional site included then this would 
need to be notified to the REC via submission of a substantial amendment. 
 
Management permission or approval must be obtained from each host organisation prior to the 
start of the study at the site concerned. 
 
Management permission ("R&D approval") should be sought from all NHS organisations 





involved in the study in accordance with NHS research governance arrangements. 
 
Guidance on applying for NHS permission for research is available in the Integrated 
Research Application System or at http://www.rdforum.nhs.uk. 
 
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites ("participant identification centre"), guidance should be sought 
from the R&D office on the information it requires to give permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation. 
 
Sponsors are not required to notify the Committee of approvals from host organisations 
 
Registration of Clinical Trials 
 
All clinical trials (defined as the first four categories on the IRAS filter page) must be 
registered on a publically accessible database within 6 weeks of recruitment of the first 
participant (for medical device studies, within the timeline determined by the current 
registration and publication trees). 
 
There is no requirement to separately notify the REC but you should do so at the earliest 
opportunity e.g. when submitting an amendment. We will audit the registration details as 
part of the annual progress reporting process. 
 
To ensure transparency in research, we strongly recommend that all research is registered 
but for non-clinical trials this is not currently mandatory. 
 
If a sponsor wishes to contest the need for registration they should contact Catherine 
Blewett (catherineblewett@nhs.net), the HRA does not, however, expect exceptions to be 
made. Guidance on where to register is provided within IRAS. 
 
It is the responsibility of the sponsor to ensure that all the conditions are complied 
with before the start of the study or its initiation at a particular site (as applicable). 
 




The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the start of 




The final list of documents reviewed and approved by the Committee is as follows: 
 
Document Version Date 
Copies of advertisement materials for research participants 
[Appendix 5: Cover letter] 
2 13 September 2015 
Evidence of Sponsor insurance or indemnity (non NHS Sponsors 
only) [Professional Indemnity] 
2 13 September 2015 
Interview schedules or topic guides for participants [Appendix 1: 
Interview Schedule (PwHD)] 
2 13 September 2015 
Interview schedules or topic guides for participants [Appendix 2: 
Interview Schedule (Partners)] 
2 13 September 2015 
Letter from sponsor [Sponsor Letter] 1 23 July 2015 






Other [Supervisor CV] 1 29 July 2015 
Other [Review Letter] 1 03 August 2015 
Other [Appendix 8: Debrief Sheet] 2 13 September 2015 
Other [Insurance: Employers' Liability] 2 13 September 2015 
Other [Insurance: Public Liability] 2 13 September 2015 
Other [Response Letter] 1 14 September 2015 
Participant consent form [Appendix 4: Consent to contact form] 2 13 September 2015 
Participant consent form [Appendix 6: Consent form (PwHD)] 2 13 September 2015 
Participant consent form [Appendix 7: Consent form (Partners)] 2 13 September 2015 
Participant information sheet (PIS) [Appendix 3: Participant 
Information Sheet] 
2 13 September 2015 
REC Application Form [REC_Form_14092015]  14 September 2015 
Research protocol or project proposal [Research Protocol] 2 13 September 2015 
Summary CV for Chief Investigator (CI) [CV] 1 17 July 2015 
Summary CV for supervisor (student research) [Supervisor CV] 1 17 July 2015 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees and complies fully with the Standard Operating Procedures for Research 
Ethics Committees in the UK. 
 




The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
• Notifying substantial amendments 
• Adding new sites and investigators 
• Notification of serious breaches of the protocol 
• Progress and safety reports 
• Notifying the end of the study 
 
The HRA website also provides guidance on these topics, which is updated in the light of 




The Health Research Authority is continually striving to provide a high quality service to all 
applicants and sponsors. You are invited to give your view of the service you have received 
and the application procedure. If you wish to make your views known please use the 





We are pleased to welcome researchers and R&D staff at our training days – see details at  
http://www.hra.nhs.uk/hra-training/ 
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Huntington’s disease (HD) is a neurodegenerative condition causing problems with 
cognitive functioning, coordination, movement and some emotional difficulties.  It is 
suggested that around five to ten per 100,000 people are affected (Kay, Fisher & Hayden, 
2014). People are generally diagnosed between the ages of 35-55 with a life expectancy of 
around 15-20 years (Keenan, Simpson, Miedzybrodzka, Alexander & Semper, 2013) and 
have often seen their parents affected by the disease (Kremer, 2002). 
People with HD often experience emotional difficulties including depression, anxiety, 
apathy and irritability (Kirkwood, Su, Conneally & Foroud, 2001) which have the potential to 
impact on an individual’s quality of life.  For example, rates of depression have been shown 
to be high in individuals with HD with the causes for this being potentially twofold (Paulsen 
et al., 2005). Certainly one potential cause is having to adjust to living with the illness as 
well as coping with the subsequent difficulties that arise as a result of HD. Additionally, 
there is a potential biological component whereby neural mechanisms in the brain are 
affected by HD subsequently affecting mood (Paulsen et al., 2005). 
Importantly, there are significant physical and emotional consequences of HD not 
only for the individual with the disease but also for the people with whom they live (e.g., 
Aubeeluck, Buchanan & Stupple, 2012; Williams et al., 2009).  Family members often take 
on caregiving for the individual with HD and subsequently may experience a reduced quality 
of life, including lowered mood (Aubeeluck & Buchanan, 2007; McCabe, Firth & O’Connor, 
2009; Read et al., 2010), potentially as a result of witnessing a loved one become increasingly 
unwell over time and grieving for a lost relationship (Pickett, Altmaier & Paulsen, 2007). 
Indeed, depression in people with HD has been identified as being a strong predictor of 





Although for people living with HD medication is often the main approach in 
supporting people with mood difficulties, psychological interventions may provide an 
alternative way to reduce distress. Medication may not always be the preferred option for 
people with HD and there could be alternative options.  For example, in another 
neurodegenerative disease, Parkinson’s disease (PD), while medication may be used to 
support people with the psychological difficulties they experience, there is increasing 
evidence to support the use of psychological interventions in this population (Charidimou, 
Seamons, Selai & Schrag, 2011; Dobkins et al., 2011), including mindfulness-based cognitive 
therapy (MBCT; Fitzpatrick, Simpson & Smith, 2010). Due to the level of distress both 
people with HD and their partners experience, it is important to understand what people think 
about the support available and treatment they receive. 
MBCT is an eight week group therapy developed by Segal, Williams and Teasdale 
(2002) which teaches mindfulness skills through a range of practices with the aim of 
preventing the reoccurrence of depression (Gu, Strauss, Bond & Cavanagh, 2015). 
Previously MBCT has been piloted with people with Parkinson’s disease who found it 
improved their psychological well-being (Fitzpatrick, Simpson & Smith, 2010).   MBCT is 
therefore going to be piloted for individuals with HD with the aim of alleviating 
psychological distress directly in people with HD and indirectly in their partners. Although 
the partners will not be directly participating in the MBCT groups, higher levels of 
mindfulness have been shown to be associated with higher levels of satisfaction in partner 
relationships (Barnes, Brown, Krusemark, Campbell & Rogge, 2007). Furthermore, people 
engaged in MBCT have reported increased empathy and perspective taking, allowing them to 
respond more mindfully in relationships (Bihari & Mullan, 2014). 
Consequently, this study aims to investigate both individuals with HD and their 





therapy.  Participants will be recruited from those who are due to take part in the trial of 
MBCT and therefore the study will focus in particular on mindfulness and people’s 
knowledge of this, as well as their hopes and expectations for MBCT.  This study will adopt a 
qualitative methodology to obtain detailed accounts of people with HD and their partners 
understanding of psychological difficulties and expectations of psychological therapy. In 
order to address this, semi-structured interviews will be conducted and analysed by 
interpretative phenomenological analysis (IPA; Smith, 2009). 
Method 
Participants 
This study will aim to recruit between 3-6 participants with HD and 3-6 partners of a 
person with HD.  However, if one group (either people with HD or their partners) is unable to 
be recruited then up to 12 participants from the other group may be recruited. Participants 
will be recruited from the MBCT trial. The person with HD will be signed up to engage in a 
MBCT programme but does not have to have a partner to take part in the study. Furthermore, 
if an insufficient number of participants are recruited then an additional site 
may be included in the study. 
 
To participate in the present study participants must meet the following criteria: 
 
• People with HD will be signed up to participate in the MBCT trial. 
 
• Partners of those signed up to participate in the MBCT trial. 
 
• Participants must be aged 18 or over. 
 
• Participants must understand and be able to speak English. 
 
People with HD and their partners who are not signed up to engage in the MBCT 







This study will adopt a qualitative design. Semi-structured interviews with people 
with HD and their partners will be conducted prior to them engaging in the MBCT 
programme.  Interviews will be analysed by IPA (Smith, 2009), however if there is an 
insufficient number of participants (either in people with HD or their partners) then thematic 
analysis will be used to analyse the data. 
Materials 
 
The interviews will be guided by a semi-structured interview schedule (appendix 1 & 
 
2) which will be informed by previous qualitative studies which have looked at the 
effectiveness of mindfulness-based interventions (Cairns & Murray, 2015) as well as a study 
conducted with a neurological population (Fitzpatrick et al., 2010).  However, further 
questions may be asked which are sensitive to, and influenced by, participants’ responses. 
Procedure 
 
People with HD will be recruited from the MBCT trial. Potential participants will be 
informed about the research when they have opted into the MBCT trial. Those suitable for 
inclusion in the study will be provided with an information pack including a participant 
information sheet (appendix 3) and consent to contact form (appendix 4) either via post, 
email or in person by the recruiters for the main MBCT trial (Dr Fiona Eccles & Dr Jane 
Simpson), with a cover letter (appendix 5).  As partners will be recruited through the person 
with HD engaging in the MBCT programme, if they are interested, an information pack for 
the partner will be sent to the person with HD via email or post. They will then be asked to 
pass this on to their partner.  The information pack will contain an information sheet and 







contact form, email or telephone) for an initial discussion regarding the research to consider 
whether they would like to take part. 
Due to the study only requiring a small number of participants there is the potential 
for people to opt into the study once the target has been reached.  In this instance, potential 
participants will be contacted by the researcher informing them that the target sample has 
been met. 
If people with HD and their partners decide to take part in the research then a 
mutually convenient interview time will be arranged. Participants will be interviewed 
individually either at home or at a community location convenient for the participant. 
People’s partners do not have to take part in order for the person with HD to take part and 
vice versa. However, if the person with HD decides not to participate then partner will still 
be recruited in the same way via the person with HD. Before commencing the interview the 
researcher will check each participant has read the participant information sheet and go 
through the consent form (appendix 6 & 7), answering any questions participants may have. 
Participants will be interviewed prior to the person with HD engaging in the MBCT 
programme.  Interviews are anticipated to last approximately 60 minutes per person. At the 
end of the interview participants will be debriefed using the debrief sheet containing sources 
of support should they require this. 
Telephone interviews may also be conducted if participants are not able to meet. If 
this is the case, a consent form will be posted to the participant and returned prior to the 
interview. Participants will be debriefed over the phone as well as having the debrief sheet 






Following each interview, the data will be transcribed by the researcher. IPA will be 
used to analyse the data, following the stages outlined by Smith (2009).  IPA is widely used 
in psychological research and aims to explore how homogenous groups of people understand 
and make sense of their personal and social world (Smith, Flowers & Larkin, 2009). 
Interviews will be transcribed and analysed individually, in turn.  Initial notations relating to 
the data will be made in the margin which will be used to identify potential themes across 




The Lancaster University Doctorate in Clinical Psychology’s data security and storage 
policies will be followed.  Interviews will be audio recorded then transferred to a computer as 
soon as possible and stored on the University server via the VPN and password protected. At 
this point they will be deleted from the device. These recordings will be destroyed once the 
data has been transcribed, checked and analysed. During the study, transcriptions will also be 
password protected and stored on the University server.  Following submission of the 
research paper, the data (consent forms and coded data) will be scanned and stored securely 
for 10 years by the Doctorate in Clinical Psychology’s admin team, while the original paper 
copies will be destroyed. At the end of this period the data will be destroyed.  Consent to 
contact forms will be kept until participants have received a copy of the results should they 
have requested these. 
As the interviews will be conducted on a one to one basis, when lone working the 
researcher will follow the lone working policy. See  
http://www.lancaster.ac.uk/shm/study/doctoral_study/dclinpsy/new/onlinehandbook/appendic 





researcher’s contact details and information about the appointment time and duration. They 
will further be provided with contact details of the interview location and interviewee (in a 
sealed envelope, only to be opened in an emergency).  When the interview is finished the 
researcher will contact the designated person to inform them that the interview is complete. 
If they do not receive this contact then attempts will be made to contact the researcher. If 
they are unable to make contact then they can open the sealed envelope and the appropriate 
authorities will be informed. 
Ethical Concerns 
 
Ethical approval will be obtained through the National Research Ethics Service 
(NRES) and research governance approval from 
research and development department who will act as the participant 
identification centre (PIC).  All participant information will remain confidential.  The 
researcher will not have access to potential participants’ personal information until the 
participants themselves express an interest in participating in the study and provide their own 
contact details.  The researcher and their supervisors will be the only people to have access to 
the audio recordings and transcripts. This will be outlined on the participants information 
sheet and consent form. 
However, there may be the potential for participants to disclose information that 
highlights a potential risk of harm, either to themselves or others. If issues related to risk are 
disclosed then confidentiality may need to be broken and the information disclosed with the 
appropriate individuals. Again, participants will be informed of this exception to 
confidentiality prior to commencing the interview. 
While it is not expected that the research will cause participants any distress, if this 





continue.  They will also be full debriefed at the end of the interview and provided with a list 
of contacts for support. 
Timescale 
June - July 2015: Submit to ethics process. 
August – December 2015: Recruitment, data collection and analysis 
October 2015: Draft read of Introduction and Method sections. 
January – April 2016: Write up and submit drafts. 
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Appendix 4-2: Interview Schedule 
 
Understandings of psychological difficulties in Huntington’s disease and expectations of 
psychological therapy 
Semi-structured interview schedule: People with Huntington’s disease 
This interview schedule gives an indication of the topic areas to be discussed in the interview 
with example questions.  The precise questions will be dependent on participants’ responses 
and the focus of each interview will be guided in part by what is deemed important to the 
individual being interviewed. 
This interview will be conducted prior to the start of the MBCT programme.  The interviewer 
will explore the psychological therapy experiences of the participant prior to the start of the 
MBCT course. It will include their emotional and psychological wellbeing prior to either 
themselves of their partner engaging in the course as well as their expectations of the course. 
Example questions: 
Introduction 
For how long have you known that you have had the HD gene? 
Do you think you show any signs of the condition at the moment? 
Do you think having HD affects how you feel? Does this also affect your partner? 
If you have thought about how you feel, what is your understanding of psychological distress 
and where this comes from? 
Therapy expectations and experiences 
If you have ever thought about psychological therapy, do you think it could be helpful for 
people living with HD and their partners? What makes you think that? 
Have you had any previous experience of psychological therapy? 
If you have had experience, what did you find beneficial about any previous therapy you have 
received? 
Have you experienced anything similar to MBCT in the past? (i.e. mindfulness) 
When you were first approached about engaging in the MBCT trial what were your first 
thoughts about the course? 
What led to your decision to take part in the research? How were you feeling in yourself 
when you decided to take part? How was your partner feeling? 
Do you or your partner have any expectations as to what the course will be like or the impact 
it may have on you or your partner? 
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Do you expect the course to help you and/or your partner? In what way do you think it might 
help? 
Do you have any worries about the MBCT course? 
Do you think there will be an impact on your psychological and emotional wellbeing? If so, 
what? 
Do you think there will be a wider impact on you and/or your partner? (e.g. your relationship 
and/or wider family relationships). 
Conclusion 
Is there anything else you think it would be useful for us to know? 
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Appendix 4-3: Interview Schedule 
 
Understandings of psychological difficulties in Huntington’s disease and expectations of 
psychological therapy 
Semi-structured interview schedule: Partners of a person with Huntington’s disease 
This interview schedule gives an indication of the topic areas to be discussed in the interview 
with example questions.  The precise questions will be dependent on participants’ responses 
and the focus of each interview will be guided in part by what is deemed important to the 
individual being interviewed. 
This interview will be conducted prior to the start of the MBCT programme.  The interviewer 
will explore the psychological therapy experiences of the participant prior to the start of the 
MBCT course. It will include their emotional and psychological wellbeing prior to either 
themselves of their partner engaging in the course as well as their expectations of the course. 
Example questions: 
Introduction 
For how long have you known that your partner has had the HD gene? 
Do you think he/she shows any signs of the condition at the moment? 
Do you think your partner having HD affects how you feel? Does this also affect your 
partner? 
If you have thought about how you feel, what is your understanding of psychological distress 
and where this comes from? 
Therapy expectations and experiences 
If you have ever thought about psychological therapy, do you think it could be helpful for 
people living with HD and their partners? What makes you think that? 
Have you had any previous experiences of psychological therapy? 
If you have, what did you find beneficial about any previous therapy you have received? 
Have you experienced anything similar to MBCT in the past? (i.e. mindfulness) 
Has your partner ever had any psychological therapy in the past?  If so, did they find it 
helpful? 
When your partner was approached about engaging in the MBCT trial what were your first 
thoughts about the course?  What did your partner think? 
What do you think led to their decision to take part in the research? How was your partner 
feeling when they decided to take part? 
Do you or your partner have any expectations as to what the course will be like or the impact 
it may have on you or your partner? 
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Do you expect the course to help your partner? In what way do you think it might help? 
Do you have any worries about the MBCT course? 
Do you think there will be an impact on both your partners and your psychological and 
emotional wellbeing? If so, what? 
Do you think there will be a wider impact on you and/or your partner? (e.g. your relationship 
and/or wider family relationships). 
Conclusion 
Is there anything else you think it would be useful for us to know? 
 
Thanks and debrief. 
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Appendix 4-4: Participant Information Sheet 
 
 
Participant Information Sheet  
 
Understandings of psychological difficulties in Huntington’s disease and expectations of 
psychological therapy 
We would like to invite you to take part in a research study, which is being conducted as part 
of a Doctorate in Clinical Psychology.  Before you decide if you would like to take part or 
not, we would like you to understand why the research is being done and what it would 
involve for you.  We will also go through the information sheet with you and answer any 
questions you have before you decide whether you want to take part. 
What is the study about? 
People with the gene for Huntington’s disease often experience psychological difficulties 
such as low mood (depression), anxiety and irritability.  Usually they are given medication to 
help with these problems however medication may only help to a certain extent or 
alternatively some people do not want to take it.  Mindfulness-based cognitive therapy 
(MBCT) is a type of psychological therapy which has been shown to help people with 
depression and other psychological difficulties and is shortly going to be trialled with people 
with the gene for Huntington’s disease to see if it can help them.  The aim of this study is to 
understand your experiences of any previous psychological therapy and your hopes and 
expectations of the MBCT trial that either yourself or your partner will be taking part in. 
 
Why have I been approached? 
Either you or your partner has agreed to be part of the MBCT pilot trial.  We would like to 
understand what people’s previous experience and understanding of psychological therapy is 
prior to engaging in the MBCT trial.  We would also like to gain insight in what people (both 
the individual and their partner) hope to gain from psychological therapy, in particular 
MBCT.  
 
While partners of people with HD will not be taking part in the MBCT trial, we are interested 
in their hopes and expectations of the course and how they think it will impact on both their 
and their partner’s life. 
 
Do I have to take part? 
No.  It’s completely up to you to decide whether or not you take part.  If you decide not to 
take part it will not affect your clinical care or that of your partner. If you agree to take part, 
you can stop and withdraw at any time without giving a reason.  
 
What will I be asked to do if I take part? 
 
Opting in 
If you are interested in taking part then first you need to contact myself (more detail at the 
end of this information sheet) and I will tell you more about the research.  If you are still 
interested in taking part, I will come and meet with you (either at home or another location 
near you) so you can sign a consent form. 




Collecting information  
If you decide to participate we will collect some data from you prior to the course 
commencing.  We would like to do this by conducting interviews.  We would like to 
interview you so you can tell us about any previous experiences of therapy, what impact you 
think therapy will have both on yourself and your partner and how you think it will impact on 
your emotional and psychological wellbeing.  The interview would last approximately an 
hour.  You can stop the interview at any time and it can be done in two parts if you feel tired.  
The interview will be audio-recorded and then transcribed (turned into a written transcript).  
Interviews can be done either at your home or another location convenient for you.  If you are 
not able to meet then they can also be done on the phone. 
 
Will my data be confidential? 
The information you provide will be kept confidential. The data collected for this study will 
be stored securely and only the researchers conducting this study will have access to this 
data: 
o The typed version of your interview will be made anonymous by removing any 
identifying information including your name.  Anonymised direct quotations from 
your interview may be used in the reports or publications from the study, so your 
name will not be attached to them.  
o Audio recordings will be destroyed and/or deleted after they have been transcribed 
and checked  
o The files on the computer will be encrypted (that is no-one other than the researchers 
will be able to access them) and the computer itself password protected. 
o At the end of the study, written transcripts and consent forms will also be kept 
securely on the computer for ten years. 
 
There are some limits to confidentiality. If at any point during the interview you say 
something that makes us think that either you or someone else is at significant risk of harm, 
we will have to break confidentiality and speak to the person with Huntington’s disease’s 
treating clinician (Dr ……..) or a member of the research team.  If possible, we will tell you 
if we have to do this.  
 
What will happen if I decide to leave part way through? 
You can choose to stop participating in the study at any time.  If you leave the study up to 3 
weeks following the interview then your data (audio recordings and transcripts) will be 
destroyed and not used in the research.  If you leave the study after this time, then the data 
may remain in the study.  However, if you ask us to withdraw your data at any point, every 
effort will be made to do so up to the point of submission of thesis, but it may not be possible 
if your data have already been analysed.  
 
What will happen to the results? 
The results will be summarised and reported at local groups and will be submitted for 
publication in academic and/or professional journals.  If you would like a copy of the results, 
please ask the researchers.  
 
Are there any risks? 
It is not anticipated that participating in this research will cause distress. However, talking 
about your thoughts and feelings in an interview can sometimes be upsetting.  If during the 
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research interview you experience any distress, you are advised to inform the researcher 
and/or contact the resources at the end of this sheet. 
  
Are there any benefits to taking part? 
There are no known benefits of taking part in this research.  However, we hope that it will 
help us better understand the psychological therapy experiences of people living with HD and 
their partners.  We also hope it will provide some insight into the psychological therapy needs 
of people with HD and their partners and how this could impact on their emotional and 
psychological wellbeing.    
 
Who has reviewed the project? 
This study has been approved by the NHS Research Ethics Service and Central Manchester 
University Hospitals NHS Foundation Trust Research and Development department. 
 
Where can I obtain further information? How do I opt in? 
If you might be interested in participating in the study, please contact a member of the 
research team.  You can do this by email to Rachael Theed: r.theed@lancaster.ac.uk or Dr 
Fiona Eccles: f.eccles@lancaster.ac.uk , by telephone (07508406193) or please fill in the 
contact sheet and send it back in the pre-paid envelope provided. 
 
You will then be provided with more information about the project so you can decide 
whether you are interested in taking part. 
 
Complaints  
If you wish to make a complaint or raise concerns about any aspect of this study and do not 
want to speak to the researchers, you can contact:  
 
Professor Bruce Hollingsworth 









It is not anticipated that taking part in this research will cause distress. However, should you 
feel distressed as a result of taking part you can contact: 
 
Dr Fiona Eccles: f.eccles@lancaster.ac.uk   
You can also contact your GP.  
 
The following organisations may also provide advice or support. 
 
Huntington’s disease association  www.hda.org.uk 
There is lots of advice and information on their website. If you call the head office on 0151 
331 5444, they can put you in touch with your regional care advisory service. More 
information about this service is given here: http://hda.org.uk/hda/rca 




The Samaritans  www.samaritans.org 
The Samaritans offer a non-judgemental listening service. Their phone number is 08457 90 
90 90 (charges apply) or you can email them on jo@samaritans.org 
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Appendix 4-5: Consent to Contact Form 
 
Consent to Contact Form  
Understandings of psychological difficulties in Huntington’s disease and expectations of 
psychological therapy 
 
If you are interested in learning more about the study please contact a member of the research 
team. You can do this by phoning Rachael Theed directly (07508406193), by email 
(r.theed@lancaster.ac.uk) or by filling in this form and returning it in the stamped addressed 








Telephone number: ______________________________ 
 
Email address: ____________________________________ 
 
I would prefer to be contacted by (please circle):              phone        email          don’t mind 
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Appendix 4-6: Cover Letter 
 
[To be sent as email or letter, depending on usual method of contact for the participant. Email 
will come from Dr Fiona Eccles] 





Dear …………  
You have recently opted into our study of mindfulness-based cognitive therapy (MBCT) for 
people with the HD gene. We are looking forward to seeing you on the MBCT course in the 
Autumn. 
In the meantime, we have a trainee clinical psychologist, Rachael Theed, who is working 
with us and is doing a project related to the main MBCT study. She is interested to find out 
how people with HD and their partners understand the psychological difficulties that people 
with HD can experience and also what are their hopes for and expectations of the MBCT 
course. We wondered if you might also be interested in taking part in her study. 
The decision to take part or not in Rachael’s study will in no way impact on your taking part 
in the MBCT course. If you do decide to take part, Rachael will arrange to meet you and will 
take consent separately for this project. More details are found on the attached/enclosed [to 
be deleted as appropriate] participant information sheet. 
If you would like further information then please get in touch with Rachael (details on the 
participant information sheet). Alternatively you are welcome to contact Fiona for an initial 
discussion (f.eccles@lancaster.ac.uk, 01524 592807). 
Thank you for taking the time to consider this additional project and we look forward to 




Jane Simpson (Research Director DClinPsy course, Chief Investigator MBCT study) 
Fiona Eccles (Lecturer in Research Methods) 
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Appendix 4-7: Consent Form (People living with HD) 
 
 
Consent Form (People living with HD)  
 
Understandings of psychological difficulties in Huntington’s disease and expectations of 
psychological therapy 
 
We are asking if you would like to take part in a research study to investigate the views of 
people living with HD who will be participating in a trial MBCT programme regarding their 
understanding of psychological difficulties, any previous psychological therapy experiences 
and hopes for/expectations of the MBCT programme.  
 
Before you consent to participating in the study we ask that you read the participant 
information sheet and mark each box below with your initials if you agree.  If you have any 
questions or queries before signing the consent form please speak to the principal researcher, 
Rachael Theed.  Contact details are provided on the participant information sheet. 
 
 Please initial the 
box after each 
statement 
1. I confirm that I have read the participant information sheet and 
fully understand what is expected of me within this study.  
 
2. I confirm that I have had the opportunity to ask any questions and 
to have them answered.  
 
3. I understand that my participation is voluntary and that I am free 
to withdraw at any time without giving any reason, without my 
medical care or legal rights being affected.  
 
4. I understand that the data collected during the study may be 
looked at by individuals from Lancaster University, from 
regulatory authorities or the NHS Trust where it is relevant to my 
taking part in the research.  I give permission for these individuals 
to have access to this data.   
 
5. I understand that my interviews will be audio recorded and then 
made into an anonymised interview transcript. 
 
6. I understand that the information from my interviews will be 
pooled with other participants’ responses, anonymised and may be 
published. 
 
7. I consent to information from the study including quotations from 
my interviews being used in reports, conferences and training 
events.  
 
8. I understand that any information I give will remain strictly 
confidential to the researchers unless it is thought that there is a 
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risk of harm to myself or others, in which case this information 
may need to be shared with appropriate persons. 
9. I consent to Lancaster University keeping the data from the study 
for up to 10 years after the study has finished.  
 
10. I consent to take part in the above study.  
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Appendix 4-8: Consent Form (Partners of a person with HD) 
 
 
Consent Form (Partners of a person with HD)  
 
Understandings of psychological difficulties in Huntington’s disease and expectations of 
psychological therapy 
 
We are asking if you would like to take part in a research study to investigate the views of 
partners of people with HD who will be participating in a trial MBCT programme regarding 
their understanding of psychological difficulties, any previous psychological therapy 
experiences and hopes for/expectations of the MBCT programme.  
 
Before you consent to participating in the study we ask that you read the participant 
information sheet and mark each box below with your initials if you agree.  If you have any 
questions or queries before signing the consent form please speak to the principal researcher, 
Rachael Theed.  Contact details are provided on the participant information sheet. 
 
 Please initial the 
box after each 
statement 
1. I confirm that I have read the participant information sheet and 
fully understand what is expected of me within this study.  
 
2. I confirm that I have had the opportunity to ask any questions and 
to have them answered.  
 
3. I understand that my participation is voluntary and that I am free 
to withdraw at any time without giving any reason, without my 
medical care or legal rights being affected.  
 
4. I understand that the data collected during the study may be 
looked at by individuals from Lancaster University, from 
regulatory authorities or the NHS Trust where it is relevant to my 
taking part in the research.  I give permission for these individuals 
to have access to this data.   
 
5. I understand that my interviews will be audio recorded and then 
made into an anonymised interview transcript. 
 
6. I understand that the information from my interviews will be 
pooled with other participants’ responses, anonymised and may be 
published. 
 
7. I consent to information from the study including quotations from 
my interviews being used in reports, conferences and training 
events.  
 
8. I understand that any information I give will remain strictly 
confidential to the researchers unless it is thought that there is a 
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risk of harm to myself or others, in which case this information 
may need to be shared with appropriate persons. 
9. I consent to Lancaster University keeping the data from the study 
for up to 10 years after the study has finished.  
 
10. I consent to take part in the above study.  
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Understandings of psychological difficulties in Huntington’s disease and expectations of 
psychological therapy 
 
Should you feel you require any support following the interview process you can contact the 
following: 
 
Rachael Theed (07508406193) or r.theed@lancaster.ac.uk   
Dr Fiona Eccles: f.eccles@lancaster.ac.uk   
Dr Jane Simpson: j.simpson2@lancaster.ac.uk  
You can also contact your GP.  
 
The following organisations may also provide advice or support: 
Huntington’s disease association www.hda.org.uk 
There is lots of advice and information on their website. If you call the head office on 0151 
331 5444, they can put you in touch with your regional care advisory service. More 
information about this service is given here: http://hda.org.uk/hda/rca 
The Samaritans www.samaritans.org 
The Samaritans offer a non-judgemental listening service. Their phone number is 08457 90 
90 90 (charges apply) or you can email them on jo@samaritans.org 
 
Purpose of the study 
This study is concerned with the psychological therapy experiences of both people with 
Huntington’s disease (HD) and partners of people with HD.  Previous studies have shown 
that both people with HD and their partners may experience emotional and psychological 
difficulties, for example low mood, anxiety and irritability, when living with HD.  However, 
the treatment of Huntington’s disease and the difficulties arise as a result of living with HD 
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often adopts a medical focus.  This study therefore aimed to gain insight into your 
experiences of and hopes for psychological therapy.    
In this study you were asked questions about your experiences of any previous psychological 
therapy you or your partner may have received and your hopes and expectations of 
mindfulness-based cognitive therapy (MBCT).  All participants were asked similar questions 
to help us understand your views. 
Why is this important to study? 
It is important to understand the psychological therapy experiences of both people with HD 
and their partners to identify what people feel is and would be beneficial to their emotional 
and psychological wellbeing.  It may further provide evidence for the need for those with HD 
and their partners who may be struggling to be able to access psychological therapy.   
 
What if I want to know more? 
For further information regarding areas the present study is concerned with, please see the 
following papers: 
Aubeeluck, A., Buchanan, H. & Stupple, E. N. (2012). ‘All the burden on all the carers’: 
exploring quality of life with family caregivers of Huntington’s disease patients. Quality of 
Life Research, 21, 1425-1435.  
Cairns, V., & Murray, C. (2015). How do the features of Mindfulness-Based Cognitive 
Therapy contribute to positive therapeutic change? A meta-synthesis of qualitative studies. 
Behavioural and Cognitive Psychotherapy, 43 (3), 342-359. doi: 
10.1017/S1352465813000945. 
Paulsen, J.S., Nehl, C., Hoth, K.F., Kanz, J.E., Benjamin, M., Conybeare, R., … & Turner, B. 
(2005). Depression and stages of Huntington’s disease. Journal of Neuropsychiatry and 
Clinical Neurosciences, 17 (4), 496-502.  
Williams, J. K., Skirton, H., Paulsen, J. S., Tripp-Reimer, T., Jarmon, L., Mcgonigal Kenney, 
M., Birrer, E., Hennig, B. L. & Honeyford, J. (2009). The emotional experiences of family 
carers in Huntington disease. Journal of Advanced Nursing, 65, 789-798.  
 
If you have concerns about your rights as a participant in this experiment or have any further 
questions, please contact Rachael Theed at r.theed@lancaster.ac.uk  
 
Thank you again for your participation. 
 
 
